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EXECUTIVE SUMMARY 
This report, Health Consultation: Evaluation of Serum PCB Levels and Cancer Incidence 
Data, Parker Street Waste Site Neighborhood, was first released in September 2011 as a draft for 
Public Comment. The health consultation was conducted in response to neighbors that live in 
close proximity to the Parker Street Waste Site (PSWS) and school staff at New Bedford High 
and Keith Middle Schools who were concerned about the presence of environmental 
contaminants, particularly polychlorinated biphenyls (PCBs). Interested parties were given six 
weeks to submit review comments on the document to the Massachusetts Department of Public 
Health, Bureau of Environmental Health (MDPH/BEH).  MDPH/BEH received approximately 
36 pages of detailed comments.  MDPH/BEH has prepared a final report which includes 
revisions, as warranted, based on the comments received.  A Response to Comments is provided 
as an Appendix (D) to this report.  
To address community member concerns, MDPH reviewed the incidence of nine types of 
cancer that were either of particular concern to residents or, based on the medical literature, were 
suggested as possibly being associated with exposure to PCBs.  The review included the five 
census tracts (CTs) that surround the PSWS and the City of New Bedford as a whole.  In 
addition, MDPH offered blood testing to concerned residents to determine levels of PCBs in 
blood serum and to evaluate whether patterns might suggest that residence near the PSWS played 
a primary role in PCB exposures.  (While this report focuses on residents of the PSWS, MDPH 
issued a separate report to address concerns specific to the indoor environment and health at the 
New Bedford High School.) 
Serum PCB testing showed that the majority of participants who currently live or 
previously lived within the five CTs, as well as three non-resident participants that reported 
spending a significant amount of time at the PSWS, have serum PCB levels within the typical 
variation seen in the U.S. population and do not indicate unusual exposure opportunities to PCBs 
(i.e., participants fell within the 95th percentile).  According to the U.S. CDC, the 95th percentile 
of NHANES data is helpful for determining whether levels observed in public health 
investigations are unusual.  Three of the 45 participants have serum PCB results above this 
typical range.  There was no consistent pattern of increasing serum PCB levels with increasing 
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years of residence in the neighborhood around the PSWS, suggesting that location of residence 
was not a primary predictor of serum PCB levels.  Consistent with national patterns, serum 
concentrations of PCBs in participants generally increased with age but were within typical 
concentrations for the U.S. population for each age group evaluated.  Finally, the PCB congener 
patterns for each age group evaluated are consistent with what is typically seen in the U.S. 
population, suggestive of dietary sources. 
The Parker Street Waste Site is located in CT 6510.02, extending into CT 6515 on its 
southerly boundary.  For both of these census tracts, the incidence of liver cancer, the type of 
cancer with the strongest association with exposure to PCBs, was approximately the same as the 
expected rate, with a difference of one between the number of observed and expected diagnoses 
for the 25-year time period.  For both census tracts, the incidence of the majority of cancer types 
was approximately as expected and no consistent trends were seen in the incidence of any 
particular type of cancer over the 25-year span.  Therefore, for the two census tracts in closest 
proximity to the Parker Street Waste Site, the incidence rates of those types of cancer possibly 
associated with exposure to PCBs appear to be approximately as expected based on comparisons 
to the cancer experience of Massachusetts as a whole.  It is important to point out that a review 
of cancer incidence data, as was conducted in this report, applies to the population at large.  This 
type of analysis cannot be used to determine the cause of cancer in an individual.  It is used as a 
screening-level evaluation to assess whether further study is warranted.  
For the other three census tracts surrounding the Parker Street Waste Site, the incidence 
of the majority of cancer types evaluated was approximately as expected for each of the five time 
periods evaluated.  No unusual or consistent trends emerged in the three census tracts. 
When cancer incidence rates for the City of New Bedford as a whole were examined, 
some elevations were noted, particularly in lung cancer in males.  Lung cancer incidence in 
males was elevated in males primarily between 1997 and 2006.  Based on smoking history 
information reported to the Massachusetts Cancer Registry, it appears that smoking played some 
role in the incidence of this cancer in New Bedford males. 
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I. INTRODUCTION 
In March 2007, the City of New Bedford forwarded a petition signed by 32 individuals to 
the Massachusetts Department of Public Health’s (MDPH) Bureau of Environmental Health 
(BEH).1  The petition was signed by 21 New Bedford High School (NBHS) teachers and 11 
neighbors of NBHS and Keith Middle School (KMS).  The petition requested testing and/or a 
study of the area around the two schools because of concerns related to historical contamination, 
particularly polychlorinated biphenyls (PCBs), and potential health implications.  NBHS 
occupies an area that formerly contained a city dump and across Hathaway Boulevard, KMS was 
constructed on fill from the former dump.  The schools and the neighborhoods around the former 
burn dump are now part of what has become known as the Parker Street Waste Site (PSWS)2 
(TRC, 2009).  To address the concerns of residents living near PSWS, BEH undertook the 
following: 
 A review of the incidence of nine types of cancer that were either of particular 
concern to residents or, based on the medical literature, were suggested as 
possibly being associated with exposure to the major contaminants of concern at 
the PSWS.  The review included the five census tracts (CTs) that surround the 
PSWS (6509, 6510.01, 6510.02, 6511, and 6515) and the City of New Bedford as 
a whole.  
 An offer to participate in the MDPH/BEH blood testing for concerned residents 
and school staff to determine levels of PCBs in blood serum and whether patterns 
might exist to suggest that residence and/or occupation or attendance at the 
schools played a primary role in PCB exposures.  
This report first presents a summary of the results of the serum PCB testing program for 
residents of the PSWS neighborhood as well as the findings of the cancer incidence data review.  
                                                 
1 This report was supported in part by funds from a cooperative agreement with the Agency for 
Toxic Substances and Disease Registry (ATSDR), U.S. Department of Health and Human 
Services. This document has not been reviewed and cleared by ATSDR.   
2 USEPA CERCLIS ID #: MAN000105955; MassDEP RTN: 4-0015685 
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A summary and conclusions for both evaluations are also provided.  For the purposes of this 
evaluation, the PSWS neighborhood is defined as the five CTs surrounding the PSWS. (New 
Bedford has a total of 31 CTs.)  Concerns specific to the indoor environment and health at the 
NBHS, including a summary of health concerns (including cancer) and the serum PCB test 
results for NBHS staff, are addressed in a separate BEH report entitled Health Consultation: 
Evaluation of Indoor Environmental Conditions and Potential Health Impacts, New Bedford 
High School, 230 Hathaway Boulevard, New Bedford, MA.   
It is our understanding that in response to a petition request from Wasted Away (now 
Citizens Leading Environmental Action Network (CLEAN)), the federal Agency for Toxic 
Substances and Disease Registry (ATSDR) committed to conducting a public health assessment 
(PHA) of the PSWS and a Health Consultation of Walsh Field.  In these assessments, ATSDR 
reviews the environmental sampling data from the site, evaluates the ways by which people may 
come into contact with contamination at the site, and then evaluates the potential for adverse 
health effects from exposures.   
II. BACKGROUND AND COMMUNITY ENVIRONMENTAL CONCERNS 
PCBs are a group of 209 different chemicals called congeners (U.S. ATSDR 2000).  
They are stable organic chemicals used in products from the 1940s through the late 1970s for 
their non-flammability and electrical insulating properties (Balfanz et al., 1993; Currado et al., 
1998; Vorhees et al., 1999).  PCBs were also used in a wide variety of materials in buildings 
constructed before the late 1970s (MacLeod et al., 1981; Kuusisto et al., 2007).  By 1977, 
companies in the United States stopped manufacturing PCBs (U.S. ATSDR 2000).  The U.S. 
Environmental Protection Agency (EPA) officially banned the manufacture of PCBs and their 
use in open systems in 1979.  In New Bedford from 1947 to 1977, PCBs were used by Aerovox 
and Cornell-Dubilier Electronics to make transformers, capacitors and other electrical equipment 
(MDPH 1987; MDPH 1995).  Prior to the manufacturing ban, PCBs were used for a variety of 
different purposes including their use in fluorescent light ballasts (Wallace et al., 1996; Staiff et 
al., 1974; MacLeod et al., 1981; and Currado et al., 1998) and caulking or joint sealants (Kohler 
et al., 2005; Herrick et al., 2004).  Products made with PCBs before the ban may still be in use 
 3 
today in older buildings, as the federal ban did not apply to items already in place in existing 
buildings at the time of the ban (Wallace et al., 1996). 
The PSWS is a hazardous waste site consisting of approximately 122 acres.  The site 
includes the New Bedford High School (NBHS), the Keith Middle School (KMS), the former 
Keith Middle School, Dr. Paul F. Walsh Memorial Field (Walsh Field), a state-owned ice arena 
(Hetland Rink), City-owned maintenance facilities, a small number of commercial properties, 
and nearby residential neighborhoods (U.S. EPA 2011, 2012).  Some properties within the 
PSWS boundaries are impacted by fill contaminated with PCBs, polyaromatic hydrocarbons 
(PAHs), and heavy metals (including but not limited to arsenic, lead, and cadmium.)  Fill 
material originated from a former city dump located in the vicinity of the NBHS campus.  NBHS 
was constructed between 1968 and 1972 and soils displaced during construction may have been 
deposited on the lot across Hathaway Boulevard, where McCoy Field, an athletic field, was later 
built and where the KMS is now located (TRC 2009) (See Figures 1 and 2).   
The KMS was constructed during 2004-2006 and opened in 2007.  The fill used in 
McCoy Field consisted of sand and silt along with ash, asphalt, and other demolition debris; 
PCBs and PAHs were detected in this fill.  In planning for construction of the KMS, the City 
hired a consultant to investigate contamination of the property and to evaluate potential 
exposures to students and school staff and the health risks associated with exposure.  As a result, 
extensive site remediation, including the removal of contaminated soil, occurred before the KMS 
was built.  The removal actions prompted greater concern among long-term residents whose 
properties abut the area.  Steps were taken during school construction to prevent future exposures 
through the construction of a gas and liquid impermeable vapor barrier under the building and a 
passive vapor collection system.  A Long-Term Monitoring and Maintenance Implementation 
Plan (MMIP) for the KMS is currently in place to monitor the exposure management barriers as 
well as levels of PCBs and volatile organic compounds (VOCs) in indoor air, the foundation 
venting system, groundwater, and wetland sediment on KMS property (BETA 2006a and b). 
Historical and recent reports on the KMS are available on the City’s website 
(http://www.newbedford-ma.gov/McCoy/sitemap/nbhs.html). 
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Additional site investigation and clean-up activities at the PSWS and the NBHS are being 
conducted by the City’s contractor, TRC Environmental (TRC), in collaboration with EPA and 
the Massachusetts Department of Environmental Protection (MassDEP).  These activities are 
aimed at further identifying the boundaries of the PSWS, identifying and addressing any data 
gaps in environmental sampling data, evaluating any potential public health and/or 
environmental impacts, and conducting clean-up activities when indicated (U.S.EPA 2010a and 
b).  The City’s website contains numerous reports and fact sheets on on-going activities related 
to the PSWS.  The portions of the PSWS boundary that required further evaluation are illustrated 
in Figure 1 (U.S. EPA 2010c).  
III. PCB SERUM TESTING 
A. METHODS 
As previously noted, MDPH/BEH conducted blood serum PCB testing of individuals 
concerned about opportunities for exposures to PCBs from the PSWS.   
The goal of the blood sampling offer was to determine if school staff and students at New 
Bedford High School and Keith Middle School had elevated serum PCB levels compared to the 
U.S. population based on comparison with CDC’s reference ranges for the general U.S. 
population.  According to CDC, biomonitoring studies of serum PCBs can provide physicians 
and public health officials with data to evaluate whether individuals have been exposed to higher 
levels of PCBs than the general population.  The measurement of an environmental chemical, 
including PCBs, in a person’s blood or urine does not by itself mean that the chemical causes 
disease or say anything about potential risk. 
The blood serum PCB testing program consisted of two phases.  The first phase consisted 
of the administration of an exposure assessment questionnaire designed to obtain information on 
risk factors that are known to or may affect serum PCB levels (e.g. age, fish consumption, 
occupational exposures), as well as factors specific to the PSWS, such as length of residence.  
Prior to completing the exposure assessment questionnaire, MDPH/BEH required that each 
participant (or parent, in the case of children) sign a consent form (see Appendix A).  The 
questionnaire was administered by an MDPH contractor, the John Snow Institute (JSI) Center for 
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Environmental Health Studies.  Interviews occurred at the Normandin Middle School in New 
Bedford.  Interviews were conducted both in English and Portuguese, with translators trained to 
administer the questionnaire.  BEH conducted outreach activities to publicize this offer to both 
English- and Portuguese speakers.  Outreach included a BEH presentation at a Public 
Involvement Plan meeting for the PSWS, press releases, press interviews, and the distribution of 
fact sheets.   
The original intent of the first phase was to identify approximately 100 individuals most 
likely to have the highest serum PCB results based upon exposure information reported in the 
questionnaire.  MDPH/BEH planned to score each questionnaire based on its extensive 
experience in predicting serum PCB levels based on known or likely risk factors for PCB 
exposure.  Due to the low level of participation in Phase I (i.e., 124 people completed the 
exposure assessment questionnaire), MDPH/BEH decided to offer all phase one participants the 
opportunity to participate in the phase two blood testing.  Information collected by this 
questionnaire was used to evaluate serum PCB results.  In particular, information regarding age, 
place of residence, and location and length of residency were evaluated in the report.  
Information including diet, other occupational exposures, and specific routes of exposure related 
to the PSWS were also evaluated on an individual level on a case-by-case basis.   
The actual blood testing involved the collection of blood samples for serum PCB analysis 
by MDPH’s William A. Hinton State Laboratory Institute (SLI) Division of Analytical 
Chemistry.  BEH worked with the New Bedford Health Department (NBHD) to coordinate the 
blood draws.  The NBHD supplied space and some basic supplies (e.g. gauze, band aides, sharps 
disposal) for the blood draws and assisted BEH in answering participant questions.  BEH 
contracted with Favorite Healthcare Staffing, Inc. to provide phlebotomy services for the serum 
PCB testing.  Two 10-milliliter (mL) red-top BD Vacutainers® of blood were collected from 
each participant.  A fact sheet was given to each participant at the time of their appointment to 
explain the process for sample analysis (see Appendix B). 
Results of serum PCB testing were compared with biomonitoring data for the civilian 
U.S. population for the most recent period available at the time of this report (2003-2004) from 
the U.S. Centers for Disease Control (U.S. CDC) National Health and Nutrition Examination 
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Survey (NHANES).  These data provide health professionals with a reference range so that they 
can determine whether any specific individual or populations of individuals demonstrate a 
pattern of exposure to higher levels of PCBs than the general U.S. population.   
On each day of sampling, BEH transported blood samples from the NBHD to MDPH’s 
SLI in Jamaica Plain.  Sample tracking forms were completed to accompany each shipment.  SLI 
staff centrifuged the samples to extract, aliquot, and store the serum samples until all the samples 
were collected.  In addition, SLI transported sample aliquots to MDPH’s Lemuel Shattuck 
Hospital in Jamaica Plain for lipid analysis. 
The method for determination of PCB congeners was developed at CDC and transferred 
to the SLI.  The standard operating procedure (SOP AC.012) for determination of PCB 
congeners in human serum details a solvent extraction, silica gel clean-up and dual capillary 
column gas chromatographic analysis with electron capture detection.      
Quality assurance measures for the method include the analysis of reagent blanks that are 
monitored for contamination and subtracted from the samples in each run; the analysis of 
fortified serum samples, the results of which are plotted on lot & instrument specific quality 
control charts for review to determine compliance with acceptance criteria for the batch; and 
individual sample fortification with surrogate analytes that are evaluated for compliance with 
acceptable recovery criteria.  Other batch specific controls include criteria for the calibration 
curve and internal standard recovery.   
Analysis of serum samples was conducted by SLI using a congener-specific analytical 
method similar to methods used by the U.S. CDC in the national survey.  Serum PCB levels were 
reported by SLI two ways: the first is on a whole volume basis in micrograms per liter (µg/L) of 
serum and the second is on a lipid-adjusted basis in nanograms per gram (ng/g) of lipid.  
Historically, when PCBs were measured in serum, the results were reported on a whole weight 
basis only.  Currently, with advances in analytical chemistry, they are also reported on a lipid-
adjusted basis.  Blood serum contains lipids (fats) and PCBs concentrate in lipid, or fatty, 
fractions in the blood.  Because different people may have different concentrations of lipids in 
their blood, PCB concentrations in blood are adjusted (or normalized) based on the lipid content.  
This adjustment allows for comparisons of blood serum PCB levels among different people and 
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populations (U.S. CDC, 2009).  It should be noted that NHANES currently reports whole weight 
results in ng/g of serum (U.S. CDC, 2009; MDPH, 2009).  To compare SLI’s results to 
NHANES results, the SLI values were converted from whole volume (µg/L) to whole weight 
(ng/g) using the average density of serum (1.026 g/mL) (Turner, 2006).  The units, µg/L and 
ng/g, are both equivalent to parts per billion (ppb), which is used throughout the rest of the report 
for simplicity.   
To compare the New Bedford results to NHANES, a total PCB concentration was 
calculated following NHANES methodology for each of the New Bedford participants by 
summing the concentrations of the 15 most commonly detected congeners which includes two 
pair of co-congeners reported together (U.S. CDC, 2006; U.S. CDC, 2009; Patterson, 2009).  
These congeners are 52, 74, 99, 105, 118, 138/158, 146, 153, 156, 170, 180, 187, 194, 196/203, 
and 199.  It should be noted that, unlike NHANES, SLI reports congeners 138 and 158 
separately.   
To calculate total PCB levels, as well as summary statistics such as geometric means and 
percentiles, CDC assigns sample results that were not detected above the method’s limit of 
detection (LOD) a value equal to the LOD divided by square root of 2.  New Bedford 
participants’ individual serum PCB results, as well as summary statistics (e.g., geometric means 
and percentiles) were calculated using this method to be comparable to CDC summary data.  
The total serum PCB concentrations (whole weight and lipid-adjusted) for each 
participant were compared to the NHANES total PCB concentrations (whole weight and lipid-
adjusted).  Because it is well established that PCBs in serum increase with age, it is important to 
compare a participant’s serum PCB level with the comparable age group from the national data 
(12-19 years, 20-39 years, 40-59 years, and 60+ years) (U.S. CDC, 2006; Miller et al., 1991; 
Patterson et al., 2009).  When comparing to NHANES data, the following summary statistics are 
used: 
• The 50th percentile value (also known as the median).  The 50th percentile is the 
midpoint of the serum PCB levels for all NHANES participants when they are 
arranged in order from lowest to highest   
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• The 95th percentile value.  The 95th percentile represents serum PCB levels 
below which 95% of the levels measured in NHANES participants are found; 
according to the U.S. CDC, the 95th percentile is useful for determining whether 
serum PCB levels are unusual   
Due to differences among individuals, you would expect to see a range of serum PCB 
levels in the general population.  The range of concentrations reported by NHANES provides 
health professionals with information on the degree of variation that can be expected in the 
general population.  According to the U.S. CDC, the 95th percentile is useful for determining 
whether serum PCB levels are unusual.  Based on this guidance from CDC, an individual with 
serum concentrations above the 50th percentile but below the 95th percentile is within the typical 
level of variation seen in the general U.S. population.  Thus, MDPH used the 95th percentile 
value for comparison with the participants’ serum PCB results.    
In addition to quantitative comparisons, BEH also conducted a qualitative comparison of 
the specific congener pattern for New Bedford participant results to what is typically seen in the 
U.S. population based on the latest NHANES data (2003-2004) (U.S. CDC 2008).  For the 
qualitative congener pattern evaluation, MDPH visually compared the distribution of percent 
contribution of the congeners most commonly seen in serum and analyzed by SLI for all New 
Bedford participants to the percent contribution of these congeners for all ages from the 
NHANES data.  In addition, a subset of sample results was submitted to CDC for review to 
confirm that individual differences noted were within the range typically seen.   
B. RESULTS AND DISCUSSION 
1) Phase I 
One hundred and twenty-four individuals completed the initial exposure assessment 
questionnaire originally intended as a screening mechanism to identify people who had the 
greatest likelihood of exposure to PCBs.  Of the 124 individuals, 57 were current or former 
residents of the PSWS neighborhood.  The majority of interviews were completed in June 2008.  
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A small number of interviews were conducted between July 2009 and March 2010 via phone to 
accommodate residents who were out of the area at the time of the interviews.   
2) Phase II 
On January 22, 2009, BEH sent letters to the homes of all 124 individuals offering serum 
PCB testing.  A total of 91 individuals asked to participate in the serum PCB testing offer.  Of 
the 33 individuals that did not participate, 21 declined the offer, 10 were lost to follow up, and 
two had inadequate sample volume but declined an offer to reschedule sample collection.  
The majority of the participants submitted blood samples for analysis in February and 
March 2009 that were collected by the MDPH phlebotomy contractor, Favorite Healthcare 
Staffing. After the contract expired with Favorite Healthcare Staffing, three individuals 
submitted samples between April and June 2009 due to scheduling conflicts or the need for a 
sample redraw; these samples were collected independent of Favorite Healthcare Staffing due to 
expiration of their MDPH contract.  A second questionnaire was administered at the time of the 
blood draw and included questions relevant to the blood draw (e.g., weight and height).   
Out of the 91 participants that consented to and submitted blood samples, 42 individuals 
were current or former residents in the neighborhood around the PSWS and three others reported 
that they had spent a significant amount of time at the PSWS (Figure 4).  Participants are 
included in this report if, at the time of the exposure assessment interview, they were among the 
42 individuals living in the neighborhood around the PSWS.  In addition, three other individuals 
that were not residents, but reported spending a significant amount of time at the PSWS were 
included, for a total of 45 participants in the evaluation of PCB serum analyzed in relation to 
outdoor PCB exposure concerns.  As mentioned earlier, results for individuals that reported 
working at NBHS, KMS, or the former KMS (including some current and former residents 
in the neighborhood around the PSWS) are included in the separate MDPH report.  Results 
for individuals that lived in the neighborhood around the PSWS and worked at the school are 
included in both reports. 
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As previously mentioned, the neighborhood around the PSWS includes the five census 
tracts (CTs) surrounding the PSWS (6509, 6510.01, 6510.02, 6511, and 6515).  The location of 
the five CTs is illustrated in Figure 3.   
The ages of the participants included in this report ranged from 14 to 84 years at the time 
the blood samples were collected (Figure 5).  Approximately 67% of the participants were 
female and 33% male.  NHANES comparison data are available by age group or by gender.  
Summary statistics are presented in this report by age group for males and females combined.  
Tables 1 and 2 contain summary statistics for total serum PCB concentrations as whole weight 
and lipid-adjusted values, respectively.     
3) Serum PCB Levels Measured in Participants 12-19 Years Old 
Two of the 45 participants were between the ages of 12 and 19 years at the time the blood 
samples were collected.  The NHANES 50th percentile value for this age group is 0.155 ppb 
(whole weight) with a 95% confidence interval of 0.144 to 0.165 ppb and 30.8 ppb (lipid-
adjusted) with a 95% confidence interval of 28.2 to 33.4 ppb (U.S. CDC 2009).  The 95% 
confidence interval is a range of estimated values that has a 95% probability of including the true 
value for the population.  No PCB congeners were detected in the serum samples collected from 
the two participants.  Therefore the serum PCB results for participants between the ages of 12 
and 19 years do not indicate unusual PCB exposures. 
4) Serum PCB Levels Measured in Participants 20-39 Years Old 
Two of the 45 participants were between the ages of 20 and 39 years at the time the blood 
samples were collected.  The NHANES 50th percentile value for this age group is 0.322 ppb 
(whole weight) with a 95% confidence interval of 0.286 ppb to 0.352 ppb and 53.0 ppb (lipid-
adjusted) with a 95% confidence interval of 46.9 ppb to 57.7 ppb (U.S. CDC 2009).  No PCB 
congeners were detected in the serum samples collected from the two participants.  Therefore the 
serum PCB results for participants between the ages of 20 and 39 years do not indicate unusual 
PCB exposures. 
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5) Serum PCB Levels Measured in Participants 40-59 Years Old 
Twenty-one of the 45 participants were between the ages of 40 and 59 years at the time 
the blood samples were collected.  The 50th percentile serum PCB level for participants in this 
age group is 1.642 ppb (whole weight), with a range of non-detect to 4.904 ppb, and 239.9 ppb 
(lipid-adjusted), with a range of non-detect to 823.9 ppb (Figures 6 and 7).  The NHANES 50th 
percentile value for this age group is 0.927 ppb (whole weight) with a 95% confidence interval 
of 0.840 ppb - 1.058 ppb and 145.3 ppb (lipid-adjusted) with a 95% confidence interval of 128.7 
ppb - 157.9 ppb (U.S. CDC 2009).  Therefore, the median serum PCB levels, both whole weight 
and lipid-adjusted, for the participants in this age group are higher than the respective NHANES 
median/50th percentiles for the U.S. population.   
The 95th percentile serum PCB level for participants in this age group is 2.730 ppb 
(whole weight) and 568.5 ppb (lipid-adjusted).  The NHANES 95th percentile concentration for 
this age group is 2.780 ppb (whole weight) with a 95% confidence interval of 2.307 ppb to 3.663 
ppb and 402.2 ppb (lipid-adjusted) with a 95% confidence interval of 325.1 to 540.2 ppb.  
Therefore, the New Bedford participants’ 95th percentile serum PCB levels for lipid-adjusted 
results in this age group are higher than the NHANES 95th percentile for the U.S. population; 
however, the whole weight results were within the NHANES 95th percentile.  The serum PCB 
concentrations for 19 of the 21 participants in this age group are within the 95th percentile of 
serum PCB levels available from the national NHANES data for both the whole weight and 
lipid-adjusted results.  For those two individuals with serum PCB concentrations exceeding the 
NHANES 95th percentile, one participant’s whole weight and lipid-adjusted results exceed the 
95th percentile, the other participant’s lipid-adjusted results exceed the 95th percentile, but the 
participant’s whole weight results were within the 95th percentile.  Participants whose results are 
within the 95th percentile are within the range of levels measured in the NHANES 2003-2004 
survey.  As stated previously in the Methods section of this report, according to the U.S. CDC, 
the 95th percentile is useful for determining whether serum PCB levels are unusual.  Thus, serum 
PCB results for 19 of the 21 participants between the ages of 40 and 59 years are within the 
typical variation across this age group in the U.S. population and the serum PCB levels for two 
of the 21 participants are above the typical range for this age group.   
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6) Serum PCB Levels Measured in Participants 60+ Years Old 
Twenty of the 45 participants were 60 years of age or older at the time the blood samples 
were collected.  The 50th percentile serum PCB level for participants in this age group is 2.455 
ppb (whole weight), with a range of 1.276 ppb to 7.742 ppb, and 360.3 ppb (lipid-adjusted), with 
a range of 154.6 to 906.1 ppb (Figures 6 and 7).  The NHANES median/50th percentile value for 
this age group is 1.805 ppb (whole weight) with a 95% confidence interval of 1.694 ppb to 1.874 
ppb and 276.0 ppb (lipid-adjusted) with a 95% confidence interval of 251.2 ppb to 295.4 ppb 
(U.S. CDC 2009).  Therefore, the median serum PCB levels for the participants, for both whole 
weight and lipid-adjusted results, are higher than the respective NHANES median/50th 
percentiles for the U.S. population.   
The 95th percentile serum PCB level for participants in this age group is 5.015 ppb 
(whole weight) and 698.0 ppb (lipid-adjusted).  The NHANES 95th percentile concentration for 
this age group is 5.123 ppb (whole weight) with a 95% confidence interval of 4.131 ppb to 6.556 
ppb and 769.4 ppb (lipid-adjusted) with a 95% confidence interval of 600.0 to 1026.5 ppb.  
Therefore, the 95th percentile serum PCB levels for the participants, for both whole weight and 
lipid-adjusted results, are within the respective NHANES 95th percentiles for the U.S. 
population.  The serum PCB concentrations for 19 of the 20 participants in this age group are 
within the 95th percentile of serum PCB levels available from the national NHANES data for 
both the whole weight and lipid-adjusted results.  One participant’s whole weight result slightly 
exceeded the NHANES whole weight 95th percentile; however, the participant’s lipid-adjusted 
result is within the NHANES 95th percentile.  Thus, serum PCB results for 19 of the 20 
participants over 60 years of age are within the typical variation across this age group in the U.S. 
population and the serum PCB result for one of the 20 participants is slightly above the typical 
range for this age group.   
7) Qualitative Congener Pattern Evaluation 
In this report, data have been provided on total PCBs based on summing the most 
frequently detected 15 congeners.  Figure 8 shows the distribution of percent contribution of 35 
congeners most commonly seen in serum and analyzed by SLI for all New Bedford participants.  
Percent contributions are also provided in Figure 9 for all ages from the NHANES data.  The 
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congener patterns observed in New Bedford and NHANES are similar, suggesting similarities 
with what is found in the U.S. population.  In addition, individual congener patterns were 
reviewed and a subset of sample results was submitted to CDC for review to confirm that 
individual differences noted were within the range typically seen.  CDC identified one 
individual’s congener pattern as atypical and this information was communicated by MDPH to 
the individual in question.  CDC noted that the congener patterns of the majority of New Bedford 
participants appeared to be typical; suggesting that exposure in the majority of the New Bedford 
participants appeared similar to that of the general U.S. population.   
8) Serum PCB Levels Compared with Years of Residence 
As mentioned earlier, 42 of the 45 participants reported currently or previously living 
within the neighborhood surrounding the PSWS (that is, within one of the five CTs surrounding 
PSWS).  Their length of residency ranged from 3 to 63 years.  To evaluate whether length of 
residency (and by proxy, exposure to environmental contaminants in the PSWS) was associated 
with higher serum levels, participants that reported currently or previously living within the five 
CTs were grouped into two approximately equal-sized groups by determining the median of 
years of residency within the five CTs or 25 years.  The first group contains all participants that 
resided in the neighborhood around the PSWS for 3-25 years and the second group contains all 
participants that resided for 26-63 years.  Mean serum levels were calculated for each group by 
age group because, as discussed, PCBs in serum generally increase with age.  To allow for 
comparison to NHANES data, geometric means instead of arithmetic means were calculated.  
Calculating the geometric mean is a standard way of looking at biological and environmental 
data.  (Geometric means are reported in the U.S. CDC’s Fourth National Report on Human 
Exposure to Environmental Chemicals.)  Table 3 summarizes the number of participants by years 
of residence in the five CTs and by age group.   
Tables 4 and 5 and Figures 10 and 11 present summary statistics (geometric means) for 
total serum PCB concentrations by length-of-residency as whole weight and lipid-adjusted 
values, respectively.  The geometric means by years of residency for the participants in the 12–
19 year age group and the 20-30 year age group are not presented in these tables because no PCB 
congeners were detected in samples collected from participants in these age groups.  Thus this 
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analysis focuses on the 40-59 and 60+ year age groups.  The tables demonstrate that there is no 
consistent pattern of high serum concentrations with more years of residency within the five 
CTs.  For the 40-59 year age group, both the mean whole weight and lipid-adjusted values were 
lower for the participants that resided in the five CTs longest by 0.138 ppb and 68.6 ppb, 
respectively.  However, for the 60+ age group, both the mean whole weight and lipid-adjusted 
values were higher for the participants that resided in the five CTs longest by 0.313 ppb and 64.8 
ppb, respectively.  Also, as mentioned previously, there are two participants in the 40-59 year 
age group and one participant in the 60+ age group whose whole weight and/or lipid-adjusted 
serum PCB levels exceed the NHANES 95th percentile value.  The two participants in the 40-59 
year age group with serum PCB levels above the NHANES 95th percentile are in the lower 
category of years lived in the five CTs (3-25 years) and the one participant in the 60+ year age 
group with a serum PCB level above the NHANES 95th percentile is in the higher category of 
years lived in the five CTs (26-63 years).  Thus, these data do not show a consistent pattern of 
higher serum concentrations with more years lived in the 5 CTs and they suggest that length of 
residence within the five CTs was not a primary indicator of serum PCB levels.  It should be 
noted that the ability to discern differences between the groups is difficult because of the small 
number of participants and the likely contributions to serum PCB levels by other factors (e.g., 
fish consumption). 
9) Serum PCB Levels Measured in Participants Diagnosed with Cancer 
Based on information shared by participants during the exposure assessment interviews 
and a search of the Massachusetts Cancer Registry database, five of the 45 participants have been 
diagnosed with cancer since 1982. The serum PCB concentrations for all five participants were 
below the NHANES 95th percentile for their respective age groups and therefore fall within the 
range of levels measured in the NHANES 2003-2004 survey.  Thus, serum PCB concentrations 
for these five individuals diagnosed with cancer are within the typical variation in the U.S. 
population.  Among the five participants, each one was diagnosed with a different type of cancer. 
Based on the epidemiological literature, three of the 5 different types of cancer have no 
association with exposure to PCBs. More discussion on the incidence of cancer among New 
Bedford residents, including the two different types of cancer potentially associated with 
exposure to PCBs, is provided below. 
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IV. CANCER INCIDENCE ANALYSIS 
As part of this health consultation, a review was conducted of the pattern of nine cancer 
types in New Bedford as well as in each of five census tracts (CTs) which surround the PSWS 
(Figure 3). The incidence of these cancers was compared with the cancer incidence experience of 
the state of Massachusetts as a whole.   
Cancer incidence data were obtained from the Massachusetts Cancer Registry (MCR) for 
the years 1982-2006.  The MCR began collecting population-based cancer incidence data in 
January of 1982.  The 25-year time period was evaluated by assessing five time periods: 1982-
1986, 1987-1991, 1992-1996, 1997-2001, and 2002-2006; this allowed for consideration of 
possible patterns or trends as compared to the statewide cancer experience.  The nine cancer 
types included in this evaluation were selected for two reasons: 1) because of their possible 
association with exposure to PCBs, as reported in the scientific/medical literature, and 2) the 
concerns of residents of suspected elevations of some cancer types.  The types of cancer 
evaluated include the following: cancers of the biliary tract3, bladder, breast, colon/rectum, 
gallbladder, liver/intrahepatic bile duct (IBD), and lung and bronchus as well as melanoma and 
non-Hodgkin lymphoma.  Concerns about the occurrence of cancer in the PSWS neighborhood 
and the New Bedford High School have been shared by current and former staff at the high 
school, by PSWS neighbors, and by members of CLEAN.  A range of various types of cancer 
have been mentioned of concern, including some of the cancer types potentially associated with 
exposure to PCBs (such as breast cancer and non-Hodgkin lymphoma) as well as other types of 
cancer for which there is no reported association with PCBs (such as cervical and ovarian 
cancers).  For this report, MDPH evaluated those nine types of cancer that have been identified 
in the medical and epidemiological literature as possibly being associated with exposure to 
PCBs.  If exposure to PCBs at the PSWS has resulted in an increased incidence of cancer in the 
                                                 
3 The biliary tract, also known as the bile duct, is the tube that connects the liver to the small 
intestine.  The part of the biliary tract within the liver itself is known as the intrahepatic bile duct 
(IBD).  Cancers within the liver or IBD are evaluated together in this report, consistent with the 
MCR methodology. Cancers within other sections of the biliary tract are referred to in this report 
as Other Biliary Tract cancers. 
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neighborhood, it is important to focus the evaluation on those types of cancer associated with 
PCB exposure. 
In addition to calculating cancer incidence rates, a qualitative analysis of the geographic 
distribution of individuals diagnosed with each of the nine types of cancer was conducted by 
mapping their residence at time of diagnosis.  This was done to assess whether the geographic 
pattern of any particular type of cancer in any of the census tracts of interest appeared unusual 
such that environmental factors were likely to play a primary role in their development.  
Available risk factor information from the MCR related to age at diagnosis and gender, as well 
as other factors related to the development of cancer such as smoking and occupation, was 
reviewed in those instances where the incidence rate of a particular cancer type was higher than 
expected.  This information was evaluated to compare known or established risk factor patterns, 
as reported in the medical and epidemiological literature for particular cancer types, to risk factor 
information for individuals diagnosed in New Bedford and to assess whether any unusual 
patterns existed among individuals diagnosed in New Bedford.   
The information described in this report is a descriptive analysis of cancer incidence data 
and cannot be used to establish a causal link between a particular risk factor and the development 
of cancer, nor can it establish the cause of any one individual’s diagnosis.  However, information 
from such descriptive analyses can be useful in determining whether or not a common etiology 
(or cause) of cancers is possible and can serve to identify areas where further public health 
investigations or actions may be warranted.  Such actions may include follow-up environmental 
investigations or, when an excess of well-established risk factors associated with a disease in a 
certain geographic area has been identified, public health intervention activities (e.g., cancer 
screening, smoking cessation, etc). 
 A. METHODS 
1) Case Identification/Definition 
Cancer incidence data (i.e., reports of new cancer diagnoses) for New Bedford and the 
five census tracts included for analysis were obtained from the MCR, a division of the MDPH 
Bureau of Health Information, Statistics, Research and Evaluation (BHISRE).  As mentioned, the 
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MCR is a population-based surveillance system that began collecting information in 1982 on 
Massachusetts residents diagnosed with cancer in the state.  All newly diagnosed cancer cases 
among Massachusetts residents are required by law to be reported to the MCR within 6 months 
of the date of diagnosis (M.G.L. c.111 s.111B).   
Although the medical and epidemiological evidence is sometimes conflicting for several 
of the cancer types evaluated in this report, and more research is needed to better understand the 
possible association with exposure to PCBs, most health agencies have concluded that PCBs may 
reasonably be expected to cause cancer. As stated earlier, nine cancer types were evaluated in 
this investigation, including cancers of the biliary tract, bladder, breast, colon/rectum, 
gallbladder, liver/intrahepatic bile duct (IBD), and lung and bronchus as well as melanoma and 
non-Hodgkin lymphoma. [Coding for these cancer types follows the International Classification 
of Diseases for Oncology (ICD-O) system. See Appendix C for the incidence coding definitions 
used in this report.] The strength of the scientific evidence on whether exposure to PCBs can 
result in an increased risk of a particular type of cancer varies significantly for the different 
cancer types included in this investigation.  Liver cancer, by far, has the strongest evidence in the 
medical/epidemiological literature of an association with exposure to PCBs (U.S. ATSDR 2000).  
Following liver cancer, there is some evidence that the following types of cancer may also be 
associated with exposure to PCBs:  biliary tract, melanoma, non-Hodgkin lymphoma, colo-
rectal, and breast cancer (Schottenfeld and Fraumeni 2006; U.S. ATSDR 2000).  The scientific 
evidence that exposure to PCBs may result in an increased risk of lung, gallbladder, or bladder 
cancer appears to be the weakest (ATSDR 2000).   
In ATSDR’s Toxicological Profile for Polychlorinated Biphenyls (ATSDR 2000), it 
summarizes its extensive review of approximately 1,800 human and animal studies that have 
been conducted to evaluate the potential for exposure to PCBs to cause cancer. It concludes the 
following: 
 “Based on indications of PCB-related cancer at several sites, particularly the liver, 
biliary tract, intestines, and skin (melanoma), the human studies provide suggestive 
evidence that PCBs are carcinogenic. There is unequivocal evidence that PCBs are 
hepatocarcinogenic in animals.” 
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MDPH included these four types of cancer in its evaluation as well as five additional 
types of cancer for which the evidence of an association with PCB exposure is not as strong.  
These include: non-Hodgkin lymphoma and breast, lung, gallbladder, and bladder cancers.  In 
addition to reviewing the findings of ATSDR’s Toxicological Profile for PCBs, MDPH also 
reviewed the evaluations of other cancer epidemiology experts on the types of cancer potentially 
associated with exposure to PCBs, particularly those reported in Cancer Epidemiology and 
Prevention, a comprehensive book on what is known about the risk factors and causes of a wide 
variety of cancers, including those associated with exposure to PCBs.  In Cancer Epidemiology 
and Prevention, the authors report liver and biliary tract cancers as well as melanoma and non-
Hodgkin lymphoma as types of cancer with evidence of an association with PCB exposure.  As 
previously stated, MDPH evaluated these four types of cancer as well.  
All diagnoses reported to the MCR as primary cancers were included in this analysis.  
Cancers that occur as the result of the metastases or the spread of a primary site cancer to another 
location in the body are not considered as a separate cancer and were, therefore, not included.  
Individuals diagnosed with cancer were selected for inclusion based on their residential address 
reported to the hospital or reporting medical facility at the time of diagnosis. 
The term "cancer" is used to describe a variety of diseases associated with abnormal cell 
and tissue growth.  Epidemiologic studies have revealed that different types of cancer are 
individual diseases with separate causes, risk factors, characteristics and patterns of survival 
(Berg 1996).  Cancers are classified by the location in the body where the disease originated (the 
primary site) and the tissue or cell type of the cancer (histology).  Therefore, each of the cancer 
types reviewed in this report was evaluated separately.  
It should be noted that duplicate records have been eliminated from the MCR data used in 
this report.  Duplicate cases are additional reports of the same primary site cancer diagnosed in 
an individual by another health-care provider.  The decision that a case was a duplicate and 
should be excluded from the analysis was made by the MCR after consulting with the reporting 
hospital/diagnostic facility and obtaining additional information regarding the histology and/or 
pathology of the case.  However, reports of individuals with multiple primary site cancers were 
included as separate cases in this report.  In general, a diagnosis of a multiple primary cancer is 
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defined by the MCR as a new cancer in a different location in the body or a new cancer of the 
same histology (cell type) as an earlier cancer, if diagnosed in the same primary site (original 
location in the body) more than 2 months after the initial diagnosis (MCR 2003).   
2) Calculation of Standardized Incidence Ratios (SIRs) 
To determine whether an elevation in cancer incidence occurred among individuals 
diagnosed with cancer in New Bedford or the five CTs surrounding the Parker Street Waste Site, 
cancer incidence data were tabulated by gender according to eighteen age groups to compare the 
observed number of cancer diagnoses to the number that would be expected based on the 
statewide cancer rate.  Standardized incidence ratios (SIRs) were calculated for the five time 
periods, for each of the nine cancer types, for the City as a whole and the five CTs, in order to 
evaluate patterns or trends in cancer incidence as compared to the statewide cancer experience. 
To calculate an SIR, it is necessary to obtain accurate population information.  The 
population figures used in this analysis were interpolated based on 1980, 1990, and 2000 U.S. 
census data for New Bedford (U.S. DOC 1980, 1990, and 2000), as well as 2010 projected 
census data.  Midpoint population estimates were calculated for each time period evaluated (i.e., 
1984, 1989, 1994, 1999, and 2004).  To estimate the population between census years, an 
assumption was made that the change in population occurred at a constant rate throughout the 
ten-year interval between each census.4 
A CT is a geographic subdivision of a city or town designated by the United States 
Census Bureau.  Because age group and gender-specific population information is necessary to 
calculate incidence rates, the CT is the smallest geographic area for which cancer rates can be 
accurately calculated.  Specifically, a CT is a smaller statistical subdivision of a county as 
defined by the U.S. Census Bureau.  CTs usually contain between 1,500 and 8,000 persons and 
are designed to be homogenous with respect to population characteristics (U.S. DOC 2000).  
New Bedford census tracts are depicted in Figure 3. 
                                                 
4 Using slightly different population estimates or statistical methodologies, such as grouping ages differently or 
rounding off numbers at different points during calculations, may produce results slightly different from those 
published in this report. 
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SIRs were not calculated for some cancer types in some time periods and/or CTs due to 
the small number of observed cases (less than five).  It is standard BHISRE policy not to 
calculate rates with fewer than five observed diagnoses due to the instability of the rate.  
However, the expected number of diagnoses was calculated during each time period and for each 
CT, and the observed and expected numbers of diagnoses were compared to determine whether 
excess numbers of cancer diagnoses were occurring. 
Stability in the context of an SIR refers to how the SIR changes when there are small 
increases or decreases in the observed or expected number of cases.  Two SIRs may have the 
same size but not the same stability. For example, an SIR of 150 may represent 6 observed 
diagnoses and 4 expected diagnoses, or 600 observed diagnoses and 400 expected diagnoses.  
(The SIR is the ratio of the number of observed diagnoses to the number of expected diagnoses 
multiplied by 100.  For example, six divided by 4 equals 1.5 as does 600 divided by 400; 1.5 
multiplied by 100 equals 150.)  Both SIRs represent a 50 percent excess of observed diagnoses. 
However, in the first instance, one or two fewer diagnoses would change the SIR a great deal, 
whereas in the second instance, even if there were several fewer diagnoses, the SIR would only 
change minimally. When the observed and expected numbers of diagnoses are relatively small, 
their ratio is easily affected by one or two diagnoses. Conversely, when the observed and 
expected numbers of diagnoses are relatively large, the value of the SIR is stable. 
3) Interpretation of a Standardized Incidence Ratio (SIR) 
An SIR is an estimate of the occurrence of cancer in a population relative to what might 
be expected if the population had the same cancer experience as a larger comparison population 
designated as "normal" or average.  Usually, the state as a whole is selected to be the comparison 
population.  Using the state of Massachusetts as a comparison population provides a stable 
population base for the calculation of incidence rates. 
Specifically, an SIR is the ratio of the observed number of cancer diagnoses in an area to 
the expected number of diagnoses multiplied by 100.  The statewide incidence rate is applied to 
the population structure of the area to calculate the number of expected cancer diagnoses.  The 
SIR is a comparison of the number of diagnoses in the specific area (i.e., city/town or census 
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tract) to the statewide rate.  Comparisons of SIRs between communities or census tracts are not 
possible because each of these areas has different population characteristics. 
Population structure, in the context of the calculation of an SIR, simply refers to the age 
and gender breakdowns (or distributions) within the New Bedford and Massachusetts 
populations.  Because cancer is a disease greatly affected by age, and also by gender, it is very 
important to account for the ages of people in the populations being studied and the numbers of 
males versus females. This process of accounting for differences in the ages of two populations 
is referred to as age adjustment or age standardization. 
An SIR of 100 indicates that the number of cancer diagnoses observed in the population 
being evaluated is equal to the number of cancer diagnoses expected in the comparison or 
"normal" population.  An SIR greater than 100 indicates that more cancer diagnoses occurred 
than were expected, and an SIR less than 100 indicates that fewer cancer diagnoses occurred than 
were expected.  Accordingly, an SIR of 150 is interpreted as 50% more cancer diagnoses than 
the expected number; an SIR of 90 indicates 10% fewer cancer diagnoses than expected. 
Caution should be exercised, however, when interpreting an SIR.  The interpretation of 
an SIR depends on both the size and the stability of the SIR.  Two SIRs can have the same size 
but not the same stability.  For example, an SIR of 150 based on four expected diagnoses and six 
observed diagnoses indicates a 50% excess in cancer, but the excess is actually only two 
diagnoses.  Conversely, an SIR of 150 based on 400 expected diagnoses and 600 observed 
diagnoses represents the same 50% excess in cancer, but because the SIR is based upon a greater 
number of diagnoses, the estimate is more stable.  It is very unlikely that 200 excess diagnoses of 
cancer would occur by chance alone.  As a result of the instability of incidence rates based on 
small numbers of diagnoses, SIRs were not calculated when fewer than five diagnoses were 
observed for a particular cancer type. 
4) Calculation of the 95% Confidence Interval 
To help interpret or measure the stability of an SIR, the statistical significance of each 
SIR was assessed by calculating a 95% confidence interval (95% CI) to determine if the 
observed number of diagnoses is “significantly different” from the expected number or if the 
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difference may be due solely to chance (Rothman and Boice 1982).  Specifically, a 95% CI is the 
range of estimated SIR values that have a 95% probability of including the true SIR for the 
population.  If the 95% CI range does not include the value 100, then the disease rate in the study 
population is statistically significantly different from the comparison or "normal" population.  
"Statistically significantly different" means there is less than a 5% chance that the observed 
difference (either increase or decrease) in the rate is the result of random fluctuation in the 
number of observed cancer diagnoses.   
For example, if a confidence interval does not include 100 and the interval is above 100 
(e.g., 105–130), there is a statistically significant excess in the number of cancer diagnoses.  
Similarly, if the confidence interval does not include 100 and the interval is below 100 (e.g., 45–
96), the number of cancer diagnoses is statistically significantly lower than expected.  If the 
confidence interval range includes 100, the true SIR may be 100.  In this case, it cannot be 
determined with certainty that the difference between the observed and expected number of 
diagnoses reflects a real cancer increase or decrease or is the result of chance.  It is important to 
note that statistical significance alone does not necessarily imply public health significance.  
Determination of statistical significance is just one tool used to interpret cancer patterns in a 
community. 
In addition to the range of the estimates contained in the confidence interval, the width of 
the confidence interval also reflects the stability of the SIR estimate.  For example, a narrow 
confidence interval, such as 103–115, allows a fair level of certainty that the calculated SIR is 
close to the true SIR for the population.  A wide interval, for instance 85–450, leaves 
considerable doubt about the true SIR, which could be much lower than or much higher than the 
calculated SIR.  This would indicate an unstable statistic.  Again, due to the instability of 
incidence rates based on small numbers of diagnoses, statistical significance was not assessed 
when fewer than five diagnoses were observed. 
5) Evaluation of Risk Factor Information 
Available information reported to the MCR related to risk factors for cancer development 
was reviewed and compared to known or established incidence patterns for the cancer types 
evaluated in this report.  This information is collected for each individual at the time of cancer 
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diagnosis and includes the individual’s age at diagnosis, the stage of disease, and the individual’s 
smoking history and occupation.  One or even several factors acting over time can be related to 
the development of cancer.  For example, tobacco use has been linked to bladder, kidney, and 
lung and bronchus cancers.  Other cancer risk factors may include lack of crude fiber in the diet, 
high fat consumption, alcohol abuse, and reproductive history.  Heredity, or family history, is an 
important factor for several cancers.  To a lesser extent, some occupational exposures, such as 
jobs involving contact with asbestos, have been shown to be carcinogenic (cancer-causing).  
Environmental contaminants have also been associated with certain types of cancer.  Available 
risk factor information from the MCR was evaluated for residents of New Bedford and the five 
CTs for cancer types determined to be elevated when compared to Massachusetts as a whole.  
However, information about personal risk factors such as family history, hormonal events, diet, 
and other factors that may also influence the development of cancer is not collected by the MCR 
or any other readily accessible source; therefore, it was not possible to evaluate these factors in 
this investigation. 
6) Determination of Geographic Distribution 
In addition to calculating SIRs, the address at the time of diagnosis for each individual 
diagnosed with one of the nine cancer types in New Bedford was geographically mapped using a 
computerized geographic information system (GIS) (ESRI 2006).  This allowed assignment of 
CT location for each individual diagnosed with cancer as well as an evaluation of the spatial 
distribution of the individuals at a smaller geographic level within CTs (i.e., neighborhoods).  
The geographic distribution was determined using a qualitative evaluation of the point pattern of 
cancer diagnoses in New Bedford, with a particular focus on CTs 6509, 6510.01, 6510.02, 6511, 
and 6515 (that is, the areas in closest proximity to the PSWS).  This evaluation included 
consideration of the population density variability of each CT through the use of GIS-generated 
population density overlays.  In instances where the address information from the MCR was 
incomplete, that is, did not include specific streets or street numbers, efforts were made to 
research those individuals’ addresses (e.g., by using telephone books issued within 2 years of an 
individual's diagnosis or searching files via the Registry of Motor Vehicles).  For confidentiality 
reasons, it is not possible to include maps in this report showing the locations of residence at 
diagnosis for individuals diagnosed with cancer.  [Note: MDPH is bound by state and federal 
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patient privacy and research laws not to reveal the name or any other identifying information of 
an individual diagnosed with cancer and reported to the MCR.] 
 B. RESULTS 
The following sections present cancer incidence rates for the community of New Bedford 
and for CTs 6509, 6510.01, 6510.02, 6511, and 6515 during the 25-year time period 1982-2006.   
The Parker Street Waste Site is located in CT 6510.02, extending into CT 6515 on its 
southerly boundary.  As mentioned, to evaluate possible trends over time as compared to the 
statewide cancer experience, these data were analyzed by five smaller time periods, 1982-1986, 
1987-1991, 1992-1996, 1997-2001, and 2002-2006.  Tables 6A through 6E summarize cancer 
incidence data for New Bedford as a whole, while Tables 7A through 7E summarize data for 
New Bedford’s CT 6510.02, Tables 8A through 8E for CT 6509, Tables 9A through 9E for CT 
6510.01, Tables 10A through 10E for CT 6511, and Tables 11A through 11E for CT 6515. 
1) New Bedford 
In the earliest time period evaluated, 1982-1986, the incidence of the nine cancer types 
was either about as expected, or in most instances, less than expected.  For five cancer types -- 
breast, colorectal, lung and bronchus, melanoma, and non-Hodgkin lymphoma – the incidence 
was statistically significantly lower than expected.  Tables 6A through 6E summarize the cancer 
incidence data for the City of New Bedford as a whole. 
During 1987-1991, the incidence of seven of the nine types of cancer evaluated was 
either about as expected or less than expected (see Table 6B). For the following cancer types, the 
incidence was statistically significantly lower than expected: bladder, breast, colorectal, 
liver/IBD, and melanoma.  Although an elevation in lung and bronchus cancer was seen in males 
during this time period, with 244 diagnoses observed compared to approximately 225 diagnoses 
expected, the difference was not statistically significant, meaning that it most likely represents 
natural variability in the number of observed diagnoses.  The incidence of two types of cancer -- 
biliary tract and gallbladder -- was elevated in females during this time period.  Ten diagnoses of 
biliary tract cancer were observed in females when approximately five would have been 
expected (SIR = 214; 95% CI: 102 - 393); this SIR is statistically significant.  For gallbladder 
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cancer in females, 15 diagnoses were observed compared to approximately six expected.  This 
finding is statistically significant (SIR = 255; 95% CI: 142 – 420). 
Between 1992 and 1996, with a few exceptions, the incidence of the cancer types 
evaluated was either about as expected or less than expected (see Table 6C).  The incidence of 
lung and bronchus cancer in females and melanoma in both genders was statistically 
significantly lower than expected.  Elevations occurred in the numbers of diagnoses of both 
colorectal and liver/IBD cancers in females during this time period; however, the differences 
were not statistically significant.  
In the time period of 1997-2001, the incidence of most of the cancer types evaluated was 
about as expected (see Table 6D). Breast cancer, melanoma, lung cancer (females only), and 
non-Hodgkin lymphoma occurred at a statistically significantly lower rate than expected during 
this time period. Elevations occurred in the numbers of diagnoses of both colorectal cancer in 
males and liver/IBD cancer in both genders; these differences were not statistically significant. A 
statistically significant elevation in the incidence of lung and bronchus cancer was observed 
among males in New Bedford during this time period, with 246 diagnoses observed compared to  
approximately 206 expected (SIR = 119, 95% CI: 105 – 135). 
During the most recent time period evaluated, 2002-2006, with the exception of two 
cancer types in males (liver/IBD and lung and bronchus), the incidence of the other types of 
cancer evaluated was about as expected (see Table 6E).  A slight elevation in biliary tract cancer 
occurred in females (8 diagnoses observed versus approximately 5 expected); the difference was 
not statistically significant. The rates of breast cancer and melanoma were statistically 
significantly lower than expected during this time period.  As in 1997-2001, a statistically 
significant elevation in the incidence of lung and bronchus cancer among males was observed 
(227 diagnoses observed versus approximately 192 expected, SIR = 118, 95% CI: 103 – 134).  A 
statistically significant elevation in the incidence of liver/IBD cancer in males was also observed 
during this time period (37 diagnoses observed versus approximately 23 expected, SIR = 163, 
95% CI: 114 – 224). 
 26 
2) Census Tract 6510.02 
The Parker Street Waste Site is located primarily in census tract 6510.02.  This census 
tract is south of CT 6510.01 and borders Dartmouth to the west (see Figure 3).  Tables 7A 
through 7E summarize the cancer incidence data for CT 6510.02. 
During the first two time periods evaluated, 1982-1986 and 1987-1991, the incidence of 
the nine cancer types evaluated was approximately as expected in CT 6510.02.  For breast cancer 
in the earliest time period, the incidence was statistically significantly lower than expected in this 
census tract. 
During 1992-1996, the incidence of most of the cancer types evaluated was about as 
expected in CT 6510.02.  Breast cancer occurred somewhat more often than expected during this 
time period, with 27 diagnoses observed when approximately 19 would have been expected; 
however, this elevation was not statistically significant.  Bladder cancer in males occurred more 
often than expected with six diagnoses observed when approximately three would have been 
expected; this elevation was not statistically significant. 
During the last two time periods, 1997-2001 and 2002-2006, the incidence of the 
majority of cancer types was approximately as expected.  No statistically significant differences 
were observed between the numbers of observed and expected diagnoses.  Although the 
incidence of lung and bronchus cancer was somewhat elevated among females in CT 6510.02, 
the differences were not statistically significant and most likely represent natural variability in 
the numbers of observed diagnoses.  Similarly, although 13 diagnoses of colorectal cancer were 
observed in females during the most current time period, when approximately eight would be 
expected, the difference was not statistically significant.  During the previous time period (1997-
2001), fewer females were diagnosed with colorectal cancer than expected (3 observed versus 9 
expected). 
3) Census Tract 6509 
Census tract 6509 is located in the center of New Bedford, to the northeast of the PSWS 
(see Figure 3).  Tables 8A through 8E summarize the cancer incidence data for CT 6509.  For 
each of the five time periods evaluated, the incidence of the nine types of cancer was 
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approximately as expected.  No statistically significant differences between the numbers of 
observed and expected diagnoses were noted during any time period.  No consistent trends were 
noted in any of the cancer types elevated. 
4) Census Tract 6510.01 
Census tract 6510.01 is located to the west of CT 6509 and northwest of the Parker Street 
Waste Site.  It borders Dartmouth to the west (see Figure 3).  Tables 9A through 9E summarize 
the cancer incidence data for CT 6510.01.   
During the first two time periods, 1982-1986 and 1987-1991, the incidence of the nine 
cancer types evaluated was either about as expected or less than expected in this census tract.   
With the exception of colorectal cancer, during 1992-1996, the incidence of cancer was at 
or near expected in CT 6510.01 for the cancer types evaluated.  A statistically significant 
elevation in the incidence of colorectal cancer was observed among males and females combined 
(28 diagnoses observed versus 18 expected, SIR = 156, 95% CI: 104 – 225).  The incidence of 
colorectal cancer was elevated among both males (12 diagnoses observed versus approximately 8 
expected) and females (16 diagnoses observed versus approximately 10 expected).   
During the last two time periods evaluated, 1997-2001 and 2002-2006, the incidence of 
the majority of cancer types was approximately as expected. During 1997-2001, there was a 
slight elevation in the incidence of colorectal cancer among males and females combined; the 
elevation was due entirely to three excess diagnoses among males. In females during the 2002-
2006 time period, there were three diagnoses of biliary tract cancer compared to less than one 
diagnosis expected. A slight elevation in lung and bronchus cancer also occurred during the 
2002-2006 time period. However, no statistically significant differences in the numbers of 
observed versus expected diagnoses of any cancer type evaluated were observed nor were any 
trends observed in these time periods. 
5)   Census Tract 6511 
Census tract 6511 is located south of CT 6509 and east of the Parker Street Waste Site 
(see Figure 3). Tables 10A through 10E summarize the cancer incidence data for CT 6511.  With 
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a few exceptions, the incidence of the nine types of cancer was approximately as expected 
throughout the 25-year time period in this census tract. 
Although the number of diagnoses of colorectal cancer in females was somewhat 
elevated during two time periods, with 12 diagnoses observed compared to approximately seven 
expected during 1987-1991 and nine diagnoses observed compared to approximately six 
expected during 1997-2001, these differences were not statistically significant.  During the 
middle time period, 1992-1996, the incidence of colorectal cancer in females was about as 
expected with seven diagnoses observed compared to approximately six expected.  During the 
remaining two time periods evaluated, the incidence of colorectal cancer in females in this 
census tract was about as expected.  The incidence of breast cancer was statistically significantly 
lower than expected during the last two time periods evaluated; during the previous three time 
periods, breast cancer incidence was as expected or lower than expected. 
6) Census Tract 6515 
The Parker Street Waste Site extends from CT 6510.02 into CT 6515 on its southerly 
boundary (see Figure 3).  Tables 11A through 11E summarize the cancer incidence data for CT 
6515. 
 During 1982-1986, with the exception of breast cancer, the incidence of the cancer types 
evaluated was either about as expected or below expected.  The incidence of breast cancer was 
somewhat elevated with 16 diagnoses observed when approximately 11 would have been 
expected; this elevation, however, was not statistically significant.  During the other four time 
periods evaluated, the incidence of breast cancer in this census tract was either lower than 
expected or as expected. 
 During the two time periods 1987-1991 and 1992-1996, all cancer types evaluated 
occurred approximately at or near expected rates. 
 In the 1997-2001 time period, all cancer types with the exception of non-Hodgkin 
lymphoma occurred at or near expected rates in CT 6515.  A statistically significant elevation in 
the incidence of NHL was observed among males and females combined (8 diagnoses observed 
versus approximately 3 expected, SIR = 283, 95% CI: 122 – 559). 
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 During 2002-2006, the incidence of all cancer types evaluated was as or near expected in 
CT 6515 with the exception of colorectal cancer.  A statistically significant elevation in the 
incidence of this cancer type was observed for males and females combined (15 diagnoses 
observed versus approximately 8 expected, SIR = 184, 95% CI: 103 – 304). Although six 
diagnoses were observed in males when approximately four were expected, the overall elevation 
was primarily due to an elevation in females with nine diagnoses observed compared to 
approximately four expected. 
A more detailed discussion of cancer incidence and an evaluation of available risk factors 
for those types of cancer found to be elevated in New Bedford or any of the 5 CTs are found in 
the following section. 
C. REVIEW OF AVAILABLE RISK FACTOR INFORMATION 
1) Biliary Tract Cancer 
During the 1987-1991 time period, an elevation in the incidence of biliary tract cancer 
was observed citywide, primarily due to an elevation among females in New Bedford (see Table 
6B). The elevation was statistically significant. 
According to the American Cancer Society (ACS), more than 2 out of every 3 individuals 
diagnosed with biliary tract cancer are over the age of 65 at diagnosis (ACS 2010a). Biliary tract 
cancers occur in certain bile ducts associated with the liver, some that have joined and are just 
leaving the liver as well as others that are located outside the liver closer to the small intestine. 
The major risk factors for biliary tract cancer include age, medical conditions that involve 
chronic inflammation of the bile duct (such as bile duct stones, ulcerative colitis, and cysts), 
obesity, family history, and exposure to thorotrast (a radioactive substance used in radiology 
until the 1950s).  The ACS reports that other possible risk factors exist for biliary tract cancer 
that require more research to better understand their role in biliary tract cancer; these include 
PCBs as well as smoking, diabetes, pancreatitis, infection with hepatitis B or C virus, and 
exposure to asbestos, dioxins, and nitrosamines (ACS 2010a). The Agency for Toxic Substances 
and Disease Registry reports that, based on evidence in animal toxicity studies and some 
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evidence in human studies, PCBs can be expected to cause cancer in the liver and the biliary tract 
(U.S. ATSDR 2000). 
Among females in New Bedford diagnosed with biliary tract cancer between 1987 and 
1991, the average age at diagnosis was 73.  Eight of the 10 females (80%) diagnosed with biliary 
tract cancer in the five years between 1987 and 1991 were above the age of 65 at diagnosis 
compared to at least 66% expected to be over 65 at diagnosis, based on national statistics for 
biliary tract cancer.  The geographic distribution of female biliary tract cancer diagnoses between 
1987 and 1991 closely followed population density patterns in New Bedford and no unusual 
spatial patterns or clustering of diagnoses were observed. The majority of the diagnoses were 
outside the five census tracts in closest proximity to the PSWS. Information on other possible 
risk factors for biliary cancer, such as medical conditions and family history, are not available 
through the MCR. 
2) Colorectal Cancer 
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in 
both men and women in the United States.  Statistically significant elevations in the incidence of 
colorectal cancer were observed in New Bedford census tracts 6510.01 during 1992-1996 and 
6515 during 2002-2006. 
According to the ACS (2010b), more than 90% of individuals diagnosed with colorectal 
cancer will be over the age of 50 at diagnosis.  The average age at diagnosis is 72 years.  Other 
known risk factors for colorectal cancer include family history, certain hereditary conditions 
(such as familial adenomatous polyposis (FAP)), personal medical conditions (such as a history 
of polyps or inflammatory bowel disease), and lifestyle factors (such as obesity and lack of 
exercise).  Up to 20% of individuals who develop colorectal cancer have family members who 
have been affected by this disease.  About 5% of individuals who develop colorectal cancer have 
an inherited genetic susceptibility to the disease. Other possible risk factors still under 
investigation include a diet high in red or processed meat, a diet low in fruits and vegetables, and 
smoking.  (It is important to note that information on hereditary conditions, medical conditions, 
and most lifestyle factors is not collected by the MCR and therefore could not be assessed for the 
purposes of this analysis.)  Although more research is needed on the possible association 
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between exposure to PCBs and an increased risk of colorectal cancer, some evidence points to 
industrial PCB exposures as being associated with colorectal cancer (U.S. ATSDR 2000).    
Twenty-eight individuals in CT 6510.01 were diagnosed with colorectal cancer between 
1992 and 1996 compared to approximately 18 expected.  Twelve were male and sixteen were 
female.  As previously stated, age is considered a risk factor for the development of colorectal 
cancer.  In CT 6510.01, the average age at diagnosis of colorectal cancer during 1992-1996 was 
72, and 27 of the 28 individuals diagnosed were above the age of 50.  These statistics are 
consistent with what would be expected, based on national statistics reported by the ACS. 
Smoking is also considered a possible risk for colorectal cancer.  Long-term smokers are 
more likely than non-smokers to develop and die from colorectal cancer. Smoking is a well-
known cause of lung cancer, but because some of the cancer-causing substances in tobacco are 
swallowed, they can increase the risk of digestive system cancers such as colorectal cancer (ACS 
2010b).  Smoking status was reported to the MCR for 18 of the 28 individuals in CT 6510.01 
diagnosed with colorectal cancer in 1992-1996.  Of these 18, 11 (61%) were current or former 
smokers at the time of their diagnosis.  Smoking history was unknown for 10 of the 28 
individuals. 
The geographic distribution of colorectal cancer diagnoses in CT 6510.01 during 1992-
1996 was evaluated.  The distribution of diagnoses closely followed population density patterns 
and no unusual clustering of diagnoses was observed. 
It is important to note that although the incidence of colorectal cancer was elevated in CT 
6510.01 during the 1992-1996 time period, the elevation did not persist in the other four time 
periods evaluated.  During the other time periods evaluated, the numbers of observed diagnoses 
of colorectal cancer were either approximately as expected or less than expected.  
Fifteen individuals (both male and female) in CT 6515 were diagnosed with colorectal 
cancer during 2002-2006 compared to approximately eight expected.  Six were male and 9 were 
female.  The average age at diagnosis of the 15 individuals was 69 and no diagnoses were 
observed among individuals below the age of 50.  Smoking status was known for 14 of the 15 
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individuals who resided in CT 6515 at the time of their diagnosis; 8 (57%) were current or 
former smokers at the time of their diagnosis. 
The geographic distribution of the fifteen individuals diagnosed with colorectal cancer in 
CT 6515 during 2002-2006 was evaluated and was found to closely follow population density 
patterns within the CT.  It is important to note that although the incidence of colorectal cancer 
was elevated in CT 6515 during the 2002-2006 time period, the elevation was not apparent in the 
earlier four time periods evaluated.  
3) Gallbladder Cancer 
During 1987-1991, a statistically significant elevation in the incidence of gallbladder 
cancer was observed citywide among New Bedford residents (males and females combined), 
primarily due to an elevation among females.  Fifteen females were diagnosed compared to 
approximately six diagnoses expected.  In the five CTs surrounding the Parker Street Waste Site, 
the incidence of gallbladder cancer was approximately as expected during the time periods 
evaluated.   
According to the ACS, the most common risk factors for gallbladder cancer are related to 
chronic inflammation of the gallbladder.  Older age is also a risk factor; the average age at 
diagnosis is 73 and 3 out of 4 individuals diagnosed with gallbladder are over the age of 65 at 
their diagnosis.  The ACS also states that gallbladder cancer is twice as common among females 
as males.  Other risk factors for gallbladder cancer include a history of gallstones; other medical 
conditions such as gallbladder polyps, calcium deposits in the gallbladder (porcelain 
gallbladder), and choldeochal cysts; and obesity.  Because gallbladder cancer is not common, 
little information exists on potential environmental or occupational exposures that may increase 
an individual’s risk of developing gallbladder cancer. Some animal studies have suggested that 
chemical compounds called nitrosamines may increase the risk of gallbladder cancer. Other 
studies have found that gallbladder cancer may be more prevalent among workers in the rubber 
and textile industries (ACS 2009a).  ATSDR reported limited evidence of an increased risk of 
gallbladder cancer from exposure to PCBs based on a study of causes of death in two capacitor 
manufacturing plants where PCBs as well as organic solvents were used (U.S. ATSDR 2000). 
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Among the 15 females diagnosed with gallbladder cancer during the 1987-1991 time 
period, the average age at diagnosis was 73, which is consistent with national statistics published 
by the ACS.  When the geographic distribution of residence at diagnosis was examined for the 
15 females, it was observed to closely follow patterns of population density in New Bedford. 
According to the ACS, more than 9 out of 10 gallbladder cancers are of the 
adenocarcinoma subtype.  Of the adenocarcinomas, approximately 6% are papillary 
adenocarcinomas.  Other less common subtypes of gallbladder cancer also exist.  Among the 15 
females diagnosed with gallbladder cancer during the 1987-1991 time period, 14 (93%) were 
diagnosed with the adenocarcinoma subtype.   
It is important to note that although the incidence of gallbladder cancer was elevated in 
New Bedford females during the 1987-1991 time period, the incidence fluctuated over the 
remaining four time periods.  Slightly fewer diagnoses were observed than expected in the 1982-
1986 and 1997-2001 time periods and slightly more diagnoses were observed than expected in 
the 1992-1996 and 2002-2006 time periods.   
4) Liver / Intrahepatic Bile Duct Cancer 
A statistically significant elevation in the incidence of liver and intrahepatic bile duct 
(IBD) cancer was observed citywide for all New Bedford residents diagnosed during 2002-2006.  
The overall elevation, however, was due to an elevation among males.  Thirty-seven diagnoses 
of liver and IBD cancer occurred in males compared to approximately 23 expected.   
According to the ACS, liver cancers are more common in males than females (2009b). 
More than 90% of individuals diagnosed with liver and IBD cancer are older than 45 years of 
age, with an average age at diagnosis of 64 years. The most common form of liver/IBD cancer is 
hepatocellular carcinoma, accounting for 75 to 90% of all diagnoses.  An additional 10–20 % of 
all liver/IBD cancers are intrahepatic cholangiocarcinomas.  A rare form, hepatoblastoma, can 
occur in children and is usually diagnosed before the age of four. 
Cirrhosis is a major risk factor for liver cancer and is usually due to chronic infection 
with either hepatitis B or C virus or heavy alcohol consumption.  Other known risk factors for 
the development of liver and IBD cancers include certain hereditary conditions (such as 
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particular metabolic disorders) and exposure to thorotrast (a substance used in radiology until the 
1950s).  Environmental exposures with links to liver and IBD cancer include occupational 
exposure to vinyl chloride (a chemical used in making some kinds of plastics), PCBs, and 
chronic exposure to drinking water contaminated with naturally occurring arsenic. Animal 
studies provide strong evidence of an increased risk of liver cancer from exposure to PCBs (U.S. 
ATSDR 2000).  In addition, although the evidence is considered suggestive, human studies in 
occupational settings suggest a link between liver cancer and PCBs. The chance of being 
exposed to arsenic depends on where you live and whether your water comes from a well or 
from a system that meets the drinking water standard for arsenic content.  According to drinking 
water quality reports available for the City of New Bedford for the years 1997 through 2008, no 
arsenic was detected in the City water supply (City of New Bedford, 1997- 2008).     
Among the 37 males in New Bedford diagnosed with liver and IBD cancer during 2002-
2006, the average age at diagnosis was 60, with 95 percent of the males being over age 45 at 
their diagnosis.  This age distribution is consistent with national statistics reported by the ACS.  
Seventy-eight percent of the diagnoses were hepatocellular carcinomas, which is also consistent 
with would be expected based on ACS statistics. The geographic distribution of liver and IBD 
diagnoses among New Bedford males during 2002-2006 was examined and found to follow 
population density patterns in the City.  In other words, the addresses of New Bedford residents 
at the time of their diagnosis were fairly evenly spread throughout those areas of the City with 
the greatest number of residents. 
In the earlier time periods evaluated (1982-1986, 1987-1991, and 1992-1996), fewer 
diagnoses of liver/IBD cancer occurred among New Bedford males than expected.  During 1997-
2001, more diagnoses occurred than expected with 24 observed compared to approximately 18 
expected; this elevation was not statistically significant. Although not a trend over the entire 25-
year time period, liver/IBD cancer incidence was elevated among New Bedford males during the 
last two time periods evaluated.  
The incidence of liver/IBD cancer among New Bedford females fluctuated somewhat 
over the 25-year time period evaluated.  In the first two time periods evaluated, the difference 
between the number of observed and expected diagnoses fluctuated between two above and three 
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below the expected number of diagnoses. In the third time period, 1992-1996, 11 diagnoses were 
observed compared to approximately six expected.  In the following time period, 1997-2001, 12 
diagnoses were observed compared to approximately nine expected. During the most recent time 
period, the incidence of liver/IBD cancer in New Bedford females was as expected (10 observed 
versus 10 expected). 
5) Lung and Bronchus Cancer 
Statistically significant elevations in the incidence of lung and bronchus cancer were 
observed citywide among males in New Bedford during the 1997-2001 and 2002-2006 time 
periods.  Among New Bedford females, the incidence of lung cancer was consistently lower than 
expected over the 25-year time period evaluated; during the first four time periods evaluated, it 
was statistically significantly lower than expected. 
According to the ACS, over two-thirds of people diagnosed with lung and bronchus 
cancer are over 65 years of age and fewer than 3% are below age 45 at diagnosis (ACS 2009c). 
The average age at the time of diagnosis is about 71 years. Between 85-90% of all lung and 
bronchus cancers are non-small cell lung cancers while 10-15% are small cell lung cancers.  
Forty percent of all lung cancers are adenocarcinomas, 25-30% are squamous cell carcinomas, 
and 10-15% are large cell carcinomas.   
The greatest risk factor for lung and bronchus cancer is smoking. Almost all small cell 
lung cancers are caused by smoking. According to the ACS, smokers are many times more likely 
than non-smokers to develop lung and bronchus cancer (ACS 2009c).  Approximately 87% of all 
lung cancers are caused directly by smoking cigarettes.  The longer a person has been smoking 
and the more cigarettes smoked per day, the greater the risk of lung cancer.  The second leading 
cause of lung and bronchus cancer among smokers is exposure to naturally occurring radon; 
among non-smokers, this is thought to be the leading cause of lung and bronchus cancer.  Other 
known risk factors include genetics, exposure to secondhand smoke, previous radiation therapy 
to the chest (e.g., for the treatment of a previous cancer such as Hodgkin disease), and 
occupational exposure to particular chemicals such as heavy metals (arsenic, beryllium, 
cadmium, chromium, and nickel), vinyl chloride, mustard gas, chloromethyl ethers, diesel 
exhaust, silica, and coal products, as well as to radioactive ores such as uranium.  ATSDR has 
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reported limited evidence of an association between lung cancer and exposure to PCBs based on 
animal studies where rats and mice were fed PCBs along with other chemicals known to be 
carcinogens (U.S. ATSDR 2000).  
Age at diagnosis was reviewed for the 473 males diagnosed with lung and bronchus 
period between 1997 and 2006.  Of the 473 males, 66 percent were over the age of 65 at the time 
of their diagnosis compared to approximately 66% nationwide.  Three percent of the New 
Bedford males were under the age of 45 at their diagnosis, which is comparable to approximately 
3% nationwide based on ACS statistics.  The age at diagnosis pattern within the New Bedford 
male population appears to closely follow national trends.   
The histologies (or tissue types) of the lung cancers among the New Bedford males were 
compared to what would be expected based on national statistics. Seventy-two percent of lung 
cancer diagnoses among New Bedford males between 1997 and 2006 were non-small cell lung 
cancers while 12% were small cell lung cancers; the relative percentages of non-small cell versus 
small cell lung cancers in these New Bedford males is consistent with the pattern of lung cancer 
subtypes seen nationwide.  Twenty-six percent of the New Bedford diagnoses were 
adenocarcinomas, 27% were squamous cell carcinomas, and 7% were large cell carcinomas.  
Although there were slightly more squamous cell carcinomas than adenocarcinomas, the 
distribution of these histologies among New Bedford males approximates those reported by the 
ACS for the U.S. as whole. 
Tobacco use history was reviewed for the male New Bedford residents diagnosed with 
lung and bronchus cancer during these two time periods. Of all males diagnosed between 1997 
and 2006, smoking history was reported to the MCR for 362 individuals.  Among the 362 
individuals, 350 (97%) were reported to the MCR as current/former smokers at the time of their 
diagnosis while 12 were reported as non-smokers. 
6) Non-Hodgkin Lymphoma 
A statistically significant elevation in the incidence of NHL among males and females 
combined was observed in CT 6515 during 1997-2001.  Eight individuals were diagnosed with 
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NHL during these five years, 4 men and 4 women, when approximately three diagnoses would 
be expected.   
Overall, the risk of non-Hodgkin lymphoma is higher in men than in women, but there 
are certain types of non-Hodgkin lymphoma that are more common in women (ACS 2009d).  
The average age at diagnosis is in the 60s, and around half of patients are older than 65 at 
diagnosis. The risk of developing non-Hodgkin lymphoma increases throughout life. Over 85% 
of all NHL diagnoses are of the subtype known as B-cell lymphomas.  
Major risk factors for NHL include older age, medical conditions involving a weakened 
immune system, and certain viral infections. Individuals who have had organ transplants or 
certain autoimmune diseases such as rheumatoid arthritis or lupus are at increased risk of 
developing NHL.  Infection with particular viral agents such as the human immunodeficiency 
virus (HIV), the human T-cell leukemia/lymphoma virus (HTLV-1), and the Epstein-Barr virus 
puts individuals at increased risk of developing NHL.  Although more research is needed, some 
studies have suggested that smoking, high-dose radiation exposures associated with atomic 
bombs and nuclear power plant accidents, and exposure to chemicals such as benzene, PCBs, 
and certain herbicides and insecticides (weed- and insect-killing substances) may be linked with 
an increased risk of NHL. A number of recent human studies have been conducted that evaluated 
non-occupationally exposed individuals, serum PCB levels, and the occurrence of NHL among 
participants in the studies.  These studies suggest that there may be an association between 
PCBs, as measured in the serum of the participants, and certain more common sub-types of 
NHL, particularly diffuse large cell lymphoma (Engel at al. 2007). 
Prior treatment for cancer can increase an individual’s risk of developing NHL.  Some 
chemotherapy drugs used to treat other cancers may increase the risk of developing leukemia or 
NHL many years later. Patients treated with radiation therapy for some other cancers, such as 
Hodgkin disease, have a slightly increased risk of developing NHL later in life. This risk is 
greater for patients treated with both radiation therapy and chemotherapy (ACS 2009d).   
Among the eight residents of CT 6515 diagnosed with NHL during 1997-2001, the 
average age at diagnosis was 58, which is slightly younger than the national average reported by 
the ACS as being in the 60s. Three of the 8 individuals (38%) were over the age of 65 when they 
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were diagnosed with NHL; the ACS reports that about half of all individuals are above 65 when 
they are diagnosed with NHL. The age pattern at diagnosis of individuals in this census tract 
with NHL approximates that of the national population.  
Seven of the 8 diagnoses (88%) were B-cell lymphomas, the predominant type of NHL in 
the U.S. population. Based on the occupational information provided by the MCR, one of the 
eight individuals diagnosed with NHL in CT 6515 may have been exposed to benzene in an 
occupational setting.  In addition, one of the eight residents of CT 6515 diagnosed with NHL 
during 1997-2001 had a previous cancer diagnosis reported to the MCR.  It is not known, 
however, whether this individual may have been treated with chemotherapeutic drugs or received 
radiation therapy for their previous cancer.  
It is important to note that although the incidence of NHL was elevated during the 1997-
2001 time period in census tract 6515, it occurred either about as expected or less frequently than 
expected during the other four time periods evaluated.  Therefore, no long-term trend was noted 
in the incidence of NHL in this census tract. 
V. DISCUSSION 
Forty-five individuals, 43 of whom are current or former residents of the PSWS 
neighborhood and three individuals who are/were not residents but reportedly had spent a 
significant amount of time at the PSWS, chose to have their blood serum tested for PCBs.  The 
majority of these individuals have serum PCB levels within the typical variation for their 
respective age groups in the U.S. population. Given the small numbers of participants, the 
MDPH/BEH cannot speak conclusively about PCB serum levels for those who were not actually 
tested.    
For the City of New Bedford as a whole, cancer incidence data spanning the 25-year time 
period showed the following: 
 With a few exceptions, no consistent trends in the incidence rates emerged over time.  
Lung cancer incidence in New Bedford males was somewhat elevated in the time period 
covering 1987-1996 and it was statistically significantly elevated in the last two time 
periods evaluated (1997-2001 and 2002-2006). Among those males whose smoking 
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history was reported to the MCR, 97% were current or former smokers at the time of 
their diagnosis.  Smoking, therefore, appears to have played a role in the incidence of 
lung cancer among New Bedford males.  The incidence of lung cancer among New 
Bedford females was consistently lower than expected over the 25-year time period. 
 The incidence of biliary tract cancer in New Bedford females was statistically 
significantly elevated during the 1987-1991 time period. Incidence rates for this type of 
cancer, however, fluctuated over the 25-year period with no consistent trend noted. 
 For both gallbladder and liver/IBD cancers, statistically significant elevations occurred in 
each cancer type in one time period.  However, a consistent trend was not seen in either 
cancer type over the 25-year time period with rates fluctuating over time. 
 The incidence of colorectal cancer was statistically significantly lower than expected 
during the first two time periods. It was elevated in the subsequent three time periods, 
however, it was not statistically significantly elevated. 
 The incidence of four types of cancer – breast, NHL, melanoma, and lung cancer in 
females – was lower than expected throughout the entire time period.  For most time 
periods, it was statistically significantly lower than expected for breast and lung cancer as 
well as melanoma.  The incidence of bladder cancer was either lower than expected or 
about as expected throughout the entire time period. 
 
MDPH reviewed cancer staging information for women diagnosed with breast cancer in 
New Bedford for the ten-year period 1996-2005, the most recent time period for which 
consistent staging methods have been used.  (Breast cancer staging methods before 1996 are 
different from those used after 1996.)  Staging describes the extent of spread of an individual’s 
cancer. From a public health perspective, earlier breast cancer staging reflects to some extent that 
women are being screened early and regularly for breast cancer whereas distant staging may 
reflect a lack of access to early screening.  In New Bedford, more women are being diagnosed 
with distant stage breast cancer (7%) compared to the state (4%); this difference is statistically 
significant and may indicate a lack of access to early screening for this disease among women in 
New Bedford. 
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For CT 6510.02, where the Parker Street Waste Site is located, the incidence of the 
majority of the nine cancer types was about as expected during the five time periods evaluated, 
constituting a 25-year span.  Although breast cancer incidence was somewhat elevated (although 
not statistically significantly elevated) during 1992-1996, with 27 diagnoses observed versus 19 
expected, in the time periods before (1982-1991) and after (1997-2006), the rate of breast cancer 
was below expected.  Similarly, in the last two time periods, although elevations were noted in 
lung and bronchus cancer in females, these elevations were not statistically significant and did 
not represent long-term trends.  Elevations in bladder cancer in males (during 1992-1996) and 
colorectal cancer in females (2002-2006) occurred in a single time period but did not occur in the 
surrounding time periods. During the five time periods, no statistically significant elevations 
occurred and no consistent trends were seen in the incidence of any particular type of cancer in 
CT 6510.02.  It is important to note that the incidence of liver cancer, the type of cancer with the 
strongest association with exposure to PCBs, was close to expected over the 25-year period with 
six diagnoses reported in CT 6510.02 compared to approximately five expected.  For the other 
five types of cancer for which there is some evidence of a link with exposure to PCBs – biliary 
tract, NHL, colorectal, melanoma, and breast cancer – the incidence of these cancer types over 
the 25-year period was below the expected rate. After liver cancer, the medical/epidemiological 
literature is strongest with respect to showing a possible association between these types of 
cancer and exposure to PCBs. 
For CT 6515, which contains the southern most area of the PSWS, the incidence of the 
cancer types evaluated was approximately as expected for each of the five time periods evaluated 
with the exception of colorectal cancer and non-Hodgkin lymphoma.  Although both colorectal 
cancer and non-Hodgkin lymphoma were statistically significantly elevated in one time period, 
these elevations did not persist over time and did not represent a consistent pattern. Except for 
the 1997-2001 time period, when eight diagnoses of NHL were observed compared to 
approximately three expected, the incidence of NHL was as expected or less than expected 
throughout the other time periods. With the exception of the most current time period, the 
incidence of colorectal cancer was approximately as expected throughout the other time periods. 
For CT 6509, the incidence of the nine types of cancer was approximately as expected for 
each of the five time periods evaluated. 
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For CT 6510.01, with one exception, the incidence of the cancer types evaluated was 
approximately as expected for the five time periods.  Colorectal cancer incidence was 
statistically significantly elevated for males and females combined during the middle time period 
of 1992-1996.  However, this elevation did not occur in the earlier time periods nor did it persist 
in subsequent time periods. 
For CT 6511, the incidence of the nine types of cancer was approximately as expected for 
each of the five time periods evaluated.  The incidence of breast cancer was statistically 
significantly lower than expected during the last two time periods evaluated. With the exception 
of breast cancer, no other consistent trends emerged in other cancer types. 
VI. CONCLUSIONS 
Serum PCB testing conducted by BEH showed that the majority of participants who 
currently live or previously lived within the five CTs, as well as the three non-resident 
participants that reported spending a significant amount of time at the PSWS, have serum PCB 
levels within the 95th percentile of serum PCB levels available from the national NHANES data.  
Three of the 45 participants had whole weight and/or lipid-adjusted results that exceeded the 
NHANES 95th percentile.  Thus, serum PCB results for 42 of the 45 participants are within the 
typical variation seen in the U.S. population and the serum PCB concentrations for three of the 
45 participants are above the typical range.   
Serum levels of PCBs reflect accumulated exposure and studies have shown that 
concentrations of PCBs in serum generally increase with age (Miller, 1991; U.S. CDC, 2009).  
Consistent with national patterns, serum concentrations of PCBs in participants generally 
increased with age but were within typical concentrations for the U.S. population for each age 
group evaluated.  There was no consistent pattern of increasing serum PCB levels with 
increasing years of residence in the neighborhood around the PSWS, suggesting that location of 
residence was not a primary predictor of serum PCB levels.  Finally, the PCB congener patterns 
for each age group evaluated are consistent with what is typically seen in the U.S. population, 
suggestive of dietary sources. 
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The Parker Street Waste Site is located in CT 6510.02, extending into CT 6515 on its 
southerly boundary.  For both of these census tracts, the incidence of liver cancer, the type of 
cancer with the strongest association with exposure to PCBs, was approximately the same as the 
expected rate, with a difference of one between the number of observed and expected diagnoses 
for the 25-year time period. For both census tracts, the incidence of the majority of cancer types 
was approximately as expected and no consistent trends were seen in the incidence of any 
particular type of cancer over the 25-year span.  Therefore, for the two census tracts in closest 
proximity to the Parker Street Waste Site, the incidence rates of those types of cancer possibly 
associated with exposure to PCBs appear to be approximately as expected based on comparisons 
to the cancer experience of Massachusetts as a whole.  It is important to point out that a review 
of cancer incidence data, as was conducted in this report, applies to the population at large. This 
type of analysis cannot be used to determine the cause of cancer in an individual.  It is used as a 
screening-level evaluation to assess whether further study is warranted.  
For the other three census tracts surrounding the Parker Street Waste Site, the incidence 
of the majority of cancer types evaluated was approximately as expected for each of the five time 
periods evaluated. No unusual or consistent trends emerged in the three census tracts. 
When cancer incidence rates for the City of New Bedford as a whole were examined, 
some elevations were noted, particularly in lung cancer in males. Lung cancer incidence in males 
was elevated in males primarily between 1997 and 2006.  Based on smoking history information 
reported to the Massachusetts Cancer Registry, it appears that smoking played some role in the 
incidence of this cancer in New Bedford males. 
VII. RECOMMENDATIONS 
To address what may be inadequate early screening for particular types of cancer in New 
Bedford – notably, breast and colorectal cancers – MDPH recommends that the New Bedford 
Health Department work with the MDPH Comprehensive Cancer Prevention and Control 
Program to increase awareness in New Bedford of the importance of early screening for cancer. 
Most colorectal cancers are preventable with routine screening tests and, when detected early, 
are almost always treatable.  Similarly, when breast cancer is found at an early stage, the chance 
of a cure is much better. Screenings, such as mammograms, can help find breast cancer early.   
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Figure 1:  EPA Parker Street Waste Site Boundaries 
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Figure 4:  Residency Status for Serum PCB Testing Offer Participants (n=45) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Age Distribution for Serum PCB Testing Offer Participants (n=45) 
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Figure 6:  Serum PCB Levels – Whole Weight (ppb; n=45) 
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Figure 7:  Serum PCB Levels – Lipid-Adjusted (ppb; n=45) 
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Figure 8:  Serum PCB Congener Pattern for all New Bedford Participants  
Lipid-Adjusted (All Ages; n=91) 
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Figure 9:  Serum PCB Congener Pattern for NHANES 2003-2004  
Lipid-Adjusted (All Ages) 
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Figure 10:  Geometric Mean Whole Weight Serum PCB Levels (ppb) 
by Years of Residency 
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Figure 11:  Geometric Mean Lipid-Adjusted Serum PCB Levels (ppb) 
by Years of Residency 
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Table 1: Summary of Median Serum PCB Concentrations (Whole Weight) 
New Bedford Residents Median and Range 
(ppb) 1, 2 NHANES Median/50th Percentile (ppb) 3 NHANES 95th Percentile (ppb) 3
Participants 1.642 0.927 2.780
40-59 yo (n=21) (ND to 4.904) (0.840, 1.058) (2.307, 3.663)
Participants 2.455 1.805 5.123
60+ yo (n=20) (1.276 to 7.742) (1.694, 1.874) (4.131, 6.556)
Notes:
yo = years old
n = number of participants
ppb = parts per billion
NHANES = National Health and Nutrition Examination Survey
The total of the 15 most frequently detected PCB congeners is presented.
1. The median concentration for the two participants between 12 and 19 years of age and the two participants between 20 and 39 years of age are not 
presented because no PCB congeners were detected in samples collected from the four participants in these age groups.
2. The range of serum PCB levels detected is presented in parentheses below the median for New Bedford residents.
3. The 95% confidence intervals appear in parentheses below both the NHANES median and 95th percentile values.  The 95% CIs presented represent the 
range of estimated values that have a 95% probability of including the true value for the population.  
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Table 2: Summary of Median Serum PCB Concentrations (Lipid-Adjusted) 
New Bedford Residents Median and Range 
(ppb) 1, 2 NHANES Median/50th Percentile (ppb) 3 NHANES 95th Percentile (ppb) 3
Participants 239.9 145.3 402.2
40-59 yo (n=21) (ND to 823.9) (128.7, 157.9) (325.1, 540.2)
Participants 360.3 276.0 769.4
60+ yo (n=20) (154.6 to 906.1) (251.2, 295.4) (600.0, 1026.5)
Notes:
yo = years old
n = number of participants
ppb = parts per billion
NHANES = National Health and Nutrition Examination Survey
The total of the 15 most frequently detected PCB congeners is presented.
1. The median concentration for the two participants between 12 and 19 years of age and the two participants between 20 and 39 years of age are not 
presented because no PCB congeners were detected in samples collected from the four participants in these age groups.
2. The range of serum PCB levels detected is presented in parentheses below the median for New Bedford residents.
3. The 95% confidence intervals appear in parentheses below both the NHANES median and 95th percentile values.  The 95% CIs presented represent the 
range of estimated values that have a 95% probability of including the true value for the population.  
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Table 3: Number of Individuals Currently or Previously Residing within the Five Census Tracts  
by Years of Residency and Age1 
3-25 Years of Residence 26-63 Years of Residence Total
(less than or equal to the 50th percentile) (greater than the 50th percentile)
12-19 1 0 1
20-39 1 1 2
40-59 11 8 19
60+ 8 12 20
Total 21 21 42
Age 
(years)
1. Three of the 45 participants in this evaluation did not report currently or previously living in the five census tracts surrounding the PSWS and are not included in this 
table.  
 
 
 
 59 
Table 4: Geometric Mean and Range of Serum PCB Concentrations (ppb; Whole Weight) 
by Years of Residency in the Five Census Tracts Surrounding the PSWS 1,2 
Age Group 3-25 Years of Residence 26-63 Years of Residence
Participants3 1.813 1.675
40-59 yo (n=11, 7) (1.112 to 4.904) (0.944 to 2.432)
Participants 2.306 2.619
60+ yo (n=8, 12) (1.493 to 4.871) (1.276 to 7.742)
Notes:
yo = years old
n = number of participants
ppb = parts per billion
NHANES = National Health and Nutrition Examination Survey
The total of the 15 most frequently detected PCB congeners is presented.
1. Three of the 45 participants in this evaluation did not report currently or previously living in the five census tracts 
surrounding the PSWS and are not included in this table.
2. Geometric means for the participants in the 12-19 and 20-39 year age groups are not presented in this table because 
no PCB congeners were detected in samples collected from participants in these age groups.
3. One participant out of 19 between the ages of 40 and 59 years of age was not included in the geometric mean 
calculations because no PCB congeners were detected in this participant's sample.  
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Table 5: Geometric Mean and Range of Serum PCB Concentrations (ppb; Lipid-Adjusted) 
by Years of Residency in the Five Census Tracts Surrounding the PSWS 1,2 
Age Group 3-25 Years of Residence 26-63 Years of Residence
Participants3 306.9 238.3
40-59 yo (n=11, 7) (179.6 to 823.9) (166.8 to 362.1)
Participants 309.7 374.5
60+ yo (n=8, 12) (190.5 to 687.0) (154.6 to 906.1)
Notes:
yo = years old
n = number of participants
ppb = parts per billion
NHANES = National Health and Nutrition Examination Survey
The total of the 15 most frequently detected PCB congeners is presented.
2. Geometric means for the participants in the 12-19 and 20-39 year age groups are not presented in this table because 
no PCB congeners were detected in samples collected from participants in these age groups.
3. One participant out of 19 between the ages of 40 and 59 years of age was not included in the geometric mean 
calculations because no PCB congeners were detected in this participant's sample.
1. Three of the 45 participants in this evaluation did not report currently or previously living in the five census tracts 
surrounding the PSWS and are not included in this table.
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TABLE 6A 
Cancer Incidence 
New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 4 9.2 NC NC  -- NC 2 3.9 NC NC  -- NC 2 5.3 NC NC  -- NC
Bladder 112 111.1 101 83  -- 121 78 78.6 99 78  -- 124 34 32.5 105 72  -- 146
Breast 275 375.4 73 * 65  -- 82 1 2.1 NC NC  -- NC 274 373.3 73 * 65  -- 83
Colon/Rectum 355 417.5 85 * 76  -- 94 149 197.3 76 * 64  -- 89 206 220.1 94 81  -- 107
Gallbladder 6 8.2 73 27  -- 160 1 2.4 NC NC  -- NC 5 5.8 86 28  -- 201
Liver / IBD 11 11.9 93 46  -- 166 5 7.6 66 21  -- 155 6 4.3 139 51  -- 302
Lung/Bronchus 273 354.5 77 * 68  -- 87 200 225.4 89 77  -- 102 73 129.1 57 * 44  -- 71
Melanoma 21 51.4 41 * 25  -- 62 17 26.2 65 38  -- 104 4 25.2 NC NC  -- NC
Non-Hodgkin Lymphoma 57 74.6 76 * 58  -- 99 28 35.8 78 52  -- 113 29 38.8 75 50  -- 107
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 6B 
Cancer Incidence 
New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 15 9.0 166 93  -- 274 5 4.3 115 37  -- 269 10 4.7 214 * 102  -- 393
Bladder 77 107.2 72 * 57  -- 90 64 76.1 84 65  -- 107 13 31.1 42 * 22  -- 71
Breast 362 425.7 85 * 77  -- 94 4 2.7 NC NC  -- NC 358 423 85 * 76  -- 94
Colon/Rectum 360 402.9 89 * 80  -- 99 176 195.6 90 77  -- 104 184 207.3 89 76  -- 103
Gallbladder 17 8.1 211 * 123  -- 338 2 2.2 NC NC  -- NC 15 5.9 255 * 142  -- 420
Liver / IBD 6 14.2 42 * 15  -- 92 4 9.5 NC NC  -- NC 2 4.7 NC NC  -- NC
Lung/Bronchus 364 378.3 96 87  -- 107 244 224.5 109 95  -- 123 120 153.8 78 * 65  -- 93
Melanoma 28 57.8 48 * 32  -- 70 15 30.2 50 * 28  -- 82 13 27.6 47 * 25  -- 81
Non-Hodgkin Lymphoma 81 89 91 72  -- 113 39 43.4 90 64  -- 123 42 45.5 92 66  -- 125
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 6C 
Cancer Incidence 
New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 10 7.3 138 66  -- 254 5 3.7 137 44  -- 319 5 3.6 139 45  -- 325
Bladder 91 95.1 96 77  -- 117 66 67 98 76  -- 125 25 28.1 89 58  -- 131
Breast 396 412.7 96 87  -- 106 1 3.5 NC NC  -- NC 395 409.2 97 87  -- 107
Colon/Rectum 377 356 106 95  -- 117 173 170.2 102 87  -- 118 204 185.8 110 95  -- 126
Gallbladder 9 7.3 124 56  -- 235 1 1.8 NC NC  -- NC 8 5.5 146 63  -- 288
Liver / IBD 20 17.5 114 70  -- 176 9 11.7 77 35  -- 146 11 5.8 188 94  -- 337
Lung/Bronchus 341 378.3 90 81  -- 100 226 208.1 109 95  -- 124 115 170.2 68 * 56  -- 81
Melanoma 27 66.1 41 * 27  -- 59 15 35.8 42 * 23  -- 69 12 30.3 40 * 20  -- 69
Non-Hodgkin Lymphoma 91 100.4 91 73  -- 111 44 49.9 88 64  -- 118 47 50.6 93 68  -- 124
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
 
 
 64 
TABLE 6D 
Cancer Incidence 
New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 6 7.7 78 29  -- 170 2 3.8 NC NC  -- NC 4 3.8 NC NC  -- NC
Bladder 77 88.8 87 68  -- 108 55 61.8 89 67  -- 116 22 27 81 51  -- 123
Breast 365 427.3 85 * 77  -- 95 3 2.7 NC NC  -- NC 362 424.6 85 * 77  -- 95
Colon/Rectum 365 351.4 104 93  -- 115 182 163.1 112 96  -- 129 183 188.2 97 84  -- 112
Gallbladder 8 7.5 107 46  -- 211 4 2.1 NC NC  -- NC 4 5.4 NC NC  -- NC
Liver / IBD 36 26.2 138 96  -- 190 24 17.7 136 87  -- 202 12 8.5 142 73  -- 248
Lung/Bronchus 396 405.9 98 88  -- 108 246 206.4 119 * 105  -- 135 150 199.5 75 * 64  -- 88
Melanoma 44 88.2 50 * 36  -- 67 28 47.5 59 * 39  -- 85 16 40.7 39 * 22  -- 64
Non-Hodgkin Lymphoma 81 105.9 76 * 61  -- 95 31 51.4 60 * 41  -- 86 50 54.5 92 68  -- 121
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 6E 
Cancer Incidence 
New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 12 10.6 113 58  -- 197 4 5.5 NC NC  -- NC 8 5.1 157 68  -- 310
Bladder 58 67.1 86 66  -- 112 43 46.2 93 67  -- 125 15 20.9 72 40  -- 118
Breast 313 391.0 80 * 71  -- 89 3 3.2 NC NC  -- NC 310 387.7 80 * 71  -- 89
Colon/Rectum 313 308.1 102 91  -- 113 143 144.8 99 83  -- 116 170 163.3 104 89  -- 121
Gallbladder 10 6.7 148 71  -- 272 2 1.9 NC NC  -- NC 8 4.9 164 71  -- 323
Liver / IBD 47 32.3 145 * 107  -- 193 37 22.8 163 * 114  -- 224 10 9.6 105 50  -- 193
Lung/Bronchus 430 400.9 107 97  -- 118 227 192.3 118 * 103  -- 134 203 208.6 97 84  -- 112
Melanoma 53 118 45 * 34  -- 59 27 62.5 43 * 28  -- 63 26 55.5 47 * 31  -- 69
Non-Hodgkin Lymphoma 97 110.7 88 71  -- 107 51 54.3 94 70  -- 123 46 56.4 82 60  -- 109
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 7A 
Cancer Incidence 
Census Tract 6510.02, New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 5 5 99 32  -- 231 3 3.6 NC NC  -- NC 2 1.4 NC NC  -- NC
Breast 8 16.1 50 * 21  -- 98 0 0.1 NC NC  -- NC 8 16 50 * 22  -- 98
Colon/Rectum 14 19 74 40  -- 124 5 9.1 55 18  -- 128 9 9.9 91 42  -- 173
Gallbladder 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 1 0.5 NC NC  -- NC 0 0.3 NC NC  -- NC 1 0.2 NC NC  -- NC
Lung/Bronchus 12 15.5 77 40  -- 135 7 10.2 69 28  -- 142 5 5.4 93 30  -- 217
Melanoma 2 2.2 NC NC  -- NC 1 1.1 NC NC  -- NC 1 1.1 NC NC  -- NC
Non-Hodgkin Lymphoma 2 3.3 NC NC  -- NC 2 1.6 NC NC  -- NC 0 1.7 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 7B 
Cancer Incidence 
Census Tract 6510.02, New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 2 5.1 NC NC  -- NC 2 3.6 NC NC  -- NC 0 1.5 NC NC  -- NC
Breast 17 18.9 90 52  -- 144 0 0.1 NC NC  -- NC 17 18.8 91 53  -- 145
Colon/Rectum 17 19.3 88 51  -- 141 8 9.4 85 37  -- 168 9 9.9 91 41  -- 172
Gallbladder 2 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 2 0.3 NC NC  -- NC
Liver / IBD 0 0.7 NC NC  -- NC 0 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 11 17.1 64 32  -- 115 7 10.5 67 27  -- 138 4 6.6 NC NC  -- NC
Melanoma 1 2.6 NC NC  -- NC 1 1.4 NC NC  -- NC 0 1.2 NC NC  -- NC
Non-Hodgkin Lymphoma 1 4.1 NC NC  -- NC 1 2 NC NC  -- NC 0 2.1 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 7C 
Cancer Incidence 
Census Tract 6510.02, New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 1 0.3 NC NC  -- NC 1 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 8 4.4 183 79  -- 361 6 3 198 72  -- 431 2 1.3 NC NC  -- NC
Breast 27 18.7 144 95  -- 210 0 0.2 NC NC  -- NC 27 18.5 146 96  -- 212
Colon/Rectum 11 16.6 66 33  -- 119 6 7.6 79 29  -- 171 5 9 56 18  -- 130
Gallbladder 0 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.3 NC NC  -- NC
Liver / IBD 1 0.8 NC NC  -- NC 0 0.5 NC NC  -- NC 1 0.3 NC NC  -- NC
Lung/Bronchus 15 16.8 89 50  -- 147 11 9.2 120 60  -- 214 4 7.6 NC NC  -- NC
Melanoma 1 2.9 NC NC  -- NC 1 1.6 NC NC  -- NC 0 1.4 NC NC  -- NC
Non-Hodgkin Lymphoma 6 4.5 133 49  -- 290 3 2.2 NC NC  -- NC 3 2.4 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 7D 
Cancer Incidence 
Census Tract 6510.02, New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 1 3.8 NC NC  -- NC 0 2.6 NC NC  -- NC 1 1.3 NC NC  -- NC
Breast 14 19.6 72 39  -- 120 0 0.1 NC NC  -- NC 14 19.4 72 39  -- 121
Colon/Rectum 11 15.7 70 35  -- 125 8 6.7 119 51  -- 235 3 9 NC NC  -- NC
Gallbladder 0 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.3 NC NC  -- NC
Liver / IBD 2 1.1 NC NC  -- NC 1 0.7 NC NC  -- NC 1 0.4 NC NC  -- NC
Lung/Bronchus 21 17.6 119 74  -- 182 8 8.4 96 41  -- 188 13 9.3 140 75  -- 240
Melanoma 3 3.7 NC NC  -- NC 1 1.9 NC NC  -- NC 2 1.8 NC NC  -- NC
Non-Hodgkin Lymphoma 3 4.6 NC NC  -- NC 1 2.1 NC NC  -- NC 2 2.5 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 7E 
Cancer Incidence 
Census Tract 6510.02, New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.5 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 1 2.9 NC NC  -- NC 1 1.9 NC NC  -- NC 0 1 NC NC  -- NC
Breast 15 18.1 83 46  -- 137 0 0.1 NC NC  -- NC 15 18.0 83 47  -- 138
Colon/Rectum 18 13.8 130 77  -- 206 5 5.9 85 27  -- 198 13 7.9 164 87  -- 280
Gallbladder 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 2 1.4 NC NC  -- NC 2 0.9 NC NC  -- NC 0 0.5 NC NC  -- NC
Lung/Bronchus 18 17.6 102 60  -- 161 6 7.8 77 28  -- 168 12 9.9 122 63  -- 213
Melanoma 4 5 NC NC  -- NC 2 2.5 NC NC  -- NC 2 2.5 NC NC  -- NC
Non-Hodgkin Lymphoma 6 4.9 123 45  -- 268 3 2.2 NC NC  -- NC 3 2.7 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 8A 
Cancer Incidence 
Census Tract 6509, New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Bladder 2 2.9 NC NC NC 0 2.0 NC NC NC 2 0.9 NC NC NC
Breast 7 10.2 69 28 141 0 0.1 NC NC NC 7 10.1 69 28 142
Colon/Rectum 5 10.9 46 15 107 5 5.1 99 32 230 0 5.8 NC NC NC
Gallbladder 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.2 NC NC NC
Liver / IBD 0 0.3 NC NC NC 0 0.2 NC NC NC 0 0.1 NC NC NC
Lung/Bronchus 9 9.3 97 44 184 7 5.8 120 48 248 2 3.5 NC NC NC
Melanoma 0 1.4 NC NC NC 0 0.7 NC NC NC 0 0.7 NC NC NC
Non-Hodgkins Lymphoma 2 2.0 NC NC NC 2 0.9 NC NC NC 0 1.1 NC NC NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 8B 
Cancer Incidence 
Census Tract 6509, New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Bladder 0 2.7 NC NC NC 0 2.0 NC NC NC 0 0.7 NC NC NC
Breast 4 11.1 NC NC NC 0 0.1 NC NC NC 4 11.0 NC NC NC
Colon/Rectum 7 9.9 70 28 145 3 5.1 NC NC NC 4 4.9 NC NC NC
Gallbladder 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Liver / IBD 0 0.4 NC NC NC 0 0.2 NC NC NC 0 0.1 NC NC NC
Lung/Bronchus 11 9.8 113 56 201 7 5.8 121 48 248 4 4.0 NC NC NC
Melanoma 2 1.6 NC NC NC 2 0.8 NC NC NC 0 0.8 NC NC NC
Non-Hodgkin Lymphoma 4 2.3 NC NC NC 4 1.1 NC NC NC 0 1.1 NC NC NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 8C 
Cancer Incidence 
Census Tract 6509, New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Bladder 1 2.3 NC NC NC 0 1.7 NC NC NC 1 0.6 NC NC NC
Breast 8 10.3 77 33 153 0 0.1 NC NC NC 8 10.2 78 34 154
Colon/Rectum 6 8.3 72 26 157 1 4.2 NC NC NC 5 4.1 122 39 285
Gallbladder 0 0.2 NC NC NC 0 0.0 NC NC NC 0 0.1 NC NC NC
Liver / IBD 0 0.4 NC NC NC 0 0.3 NC NC NC 0 0.1 NC NC NC
Lung/Bronchus 12 9.2 130 67 227 7 5.1 136 55 281 5 4.1 122 39 284
Melanoma 2 1.7 NC NC NC 1 0.9 NC NC NC 1 0.8 NC NC NC
Non-Hodgkin Lymphoma 2 2.5 NC NC NC 0 1.3 NC NC NC 2 1.2 NC NC NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 8D 
Cancer Incidence 
Census Tract 6509, New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Bladder 1 2.0 NC NC NC 0 1.5 NC NC NC 1 0.6 NC NC NC
Breast 4 10.2 NC NC NC 0 0.1 NC NC NC 4 10.1 NC NC NC
Colon/Rectum 9 7.8 116 53 220 4 3.8 NC NC NC 5 3.9 127 41 297
Gallbladder 0 0.2 NC NC NC 0 0.0 NC NC NC 0 0.1 NC NC NC
Liver / IBD 1 0.6 NC NC NC 1 0.4 NC NC NC 0 0.2 NC NC NC
Lung/Bronchus 10 9.2 108 52 199 5 4.8 104 33 242 5 4.4 113 37 264
Melanoma 1 2.2 NC NC NC 1 1.1 NC NC NC 0 1.0 NC NC NC
Non-Hodgkin Lymphoma 1 2.5 NC NC NC 0 1.2 NC NC NC 1 1.3 NC NC NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 8E 
Cancer Incidence 
Census Tract 6509, New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC NC 0 0.1 NC NC NC 0 0.1 NC NC NC
Bladder 1 1.4 NC NC NC 1 1.0 NC NC NC 0 0.4 NC NC NC
Breast 5 9.3 54 17 125 0 0.1 NC NC NC 5 9.3 54 17 126
Colon/Rectum 8 6.6 122 52 239 3 3.2 NC NC NC 5 3.4 148 48 346
Gallbladder 0 0.2 NC NC NC 0 0.0 NC NC NC 0 0.1 NC NC NC
Liver / IBD 2 0.7 NC NC NC 2 0.5 NC NC NC 0 0.2 NC NC NC
Lung/Bronchus 12 8.6 139 72 243 7 4.2 166 67 343 5 4.4 113 36 263
Melanoma 0 2.8 NC NC NC 0 1.4 NC NC NC 0 1.4 NC NC NC
Non-Hodgkin Lymphoma 3 2.5 NC NC NC 3 1.2 NC NC NC 0 1.2 NC NC NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 9A 
Cancer Incidence 
Census Tract 6510.01, New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 4 4.1 NC NC  -- NC 4 2.8 NC NC  -- NC 0 1.3 NC NC  -- NC
Breast 15 13.8 109 61  -- 179 0 0.1 NC NC  -- NC 15 13.7 109 61  -- 180
Colon/Rectum 14 15.8 89 49  -- 149 6 7.1 85 31  -- 184 8 8.7 92 40  -- 182
Gallbladder 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 0 0.4 NC NC  -- NC 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 7 12.8 55 22  -- 113 3 8 NC NC  -- NC 4 4.8 NC NC  -- NC
Melanoma 3 1.7 NC NC  -- NC 3 0.8 NC NC  -- NC 0 0.9 NC NC  -- NC
Non-Hodgkin Lymphoma 3 2.6 NC NC  -- NC 0 1.2 NC NC  -- NC 3 1.4 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 9B 
Cancer Incidence 
Census Tract 6510.01, New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 2 4.8 NC NC  -- NC 1 3.3 NC NC  -- NC 1 1.5 NC NC  -- NC
Breast 12 18.7 64 33  -- 112 0 0.1 NC NC  -- NC 12 18.6 65 33  -- 113
Colon/Rectum 17 18.7 91 53  -- 145 6 8.5 70 26  -- 153 11 10.2 108 54  -- 193
Gallbladder 0 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.3 NC NC  -- NC
Liver / IBD 1 0.6 NC NC  -- NC 1 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 18 16.5 109 65  -- 172 11 9.5 116 58  -- 208 7 7 99 40  -- 205
Melanoma 1 2.2 NC NC  -- NC 0 1.1 NC NC  -- NC 1 1.1 NC NC  -- NC
Non-Hodgkin Lymphoma 1 3.7 NC NC  -- NC 1 1.6 NC NC  -- NC 0 2.1 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 9C 
Cancer Incidence 
Census Tract 6510.01, New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 2 4.6 NC NC  -- NC 1 3.1 NC NC  -- NC 1 1.5 NC NC  -- NC
Breast 20 19.1 105 64  -- 162 0 0.2 NC NC  -- NC 20 18.9 106 64  -- 163
Colon/Rectum 28 18 156 * 104  -- 225 12 7.9 152 78  -- 265 16 10 159 91  -- 259
Gallbladder 1 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.3 NC NC  -- NC
Liver / IBD 0 0.8 NC NC  -- NC 0 0.5 NC NC  -- NC 0 0.3 NC NC  -- NC
Lung/Bronchus 20 17.6 114 69  -- 176 10 9.2 108 52  -- 199 10 8.4 120 57  -- 220
Melanoma 1 2.7 NC NC  -- NC 1 1.4 NC NC  -- NC 0 1.3 NC NC  -- NC
Non-Hodgkin Lymphoma 6 4.5 134 49  -- 292 3 2 NC NC  -- NC 3 2.5 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 9D 
Cancer Incidence 
Census Tract 6510.01, New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 1 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC 1 0.2 NC NC  -- NC
Bladder 3 4.6 NC NC  -- NC 3 3.1 NC NC  -- NC 0 1.6 NC NC  -- NC
Breast 20 20.1 99 61  -- 153 1 0.1 NC NC  -- NC 19 20 95 57  -- 148
Colon/Rectum 22 18.7 118 74  -- 178 11 7.8 140 70  -- 251 11 10.9 101 50  -- 181
Gallbladder 0 0.4 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.3 NC NC  -- NC
Liver / IBD 0 1.2 NC NC  -- NC 0 0.7 NC NC  -- NC 0 0.5 NC NC  -- NC
Lung/Bronchus 18 19.9 90 53  -- 143 8 9.5 84 36  -- 165 10 10.4 96 46  -- 177
Melanoma 3 3.7 NC NC  -- NC 3 1.9 NC NC  -- NC 0 1.8 NC NC  -- NC
Non-Hodgkin Lymphoma 4 5 NC NC  -- NC 3 2.2 NC NC  -- NC 1 2.8 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 9E 
Cancer Incidence 
Census Tract 6510.01, New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 3 0.5 NC NC  -- NC 0 0.2 NC NC  -- NC 3 0.3 NC NC  -- NC
Bladder 3 3.5 NC NC  -- NC 2 2.3 NC NC  -- NC 1 1.2 NC NC  -- NC
Breast 16 17.7 90 52  -- 147 0 0.2 NC NC  -- NC 16 17.5 91 52  -- 148
Colon/Rectum 11 16 69 34  -- 123 7 6.7 104 42  -- 214 4 9.2 NC NC  -- NC
Gallbladder 1 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.3 NC NC  -- NC
Liver / IBD 3 1.4 NC NC  -- NC 2 0.9 NC NC  -- NC 1 0.5 NC NC  -- NC
Lung/Bronchus 25 19.9 126 81  -- 186 11 8.9 123 61  -- 220 14 10.9 128 70  -- 215
Melanoma 2 4.9 NC NC  -- NC 1 2.6 NC NC  -- NC 1 2.3 NC NC  -- NC
Non-Hodgkin Lymphoma 7 5.2 134 54  -- 275 3 2.3 NC NC  -- NC 4 2.9 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 10A 
Cancer Incidence 
Census Tract 6511, New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 5 3.9 127 41  -- 296 4 2.8 NC NC  -- NC 1 1.1 NC NC  -- NC
Breast 9 13.8 65 30  -- 124 0 0.1 NC NC  -- NC 9 13.7 66 30  -- 125
Colon/Rectum 10 14.7 68 33  -- 125 4 7.1 NC NC  -- NC 6 7.6 79 29  -- 172
Gallbladder 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 0 0.4 NC NC  -- NC 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 13 12.9 101 54  -- 172 8 8.1 98 42  -- 194 5 4.8 105 34  -- 244
Melanoma 0 2 NC NC  -- NC 0 1 NC NC  -- NC 0 1 NC NC  -- NC
Non-Hodgkin Lymphoma 1 2.7 NC NC  -- NC 0 1.3 NC NC  -- NC 1 1.4 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 10B 
Cancer Incidence 
Census Tract 6511, New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 2 3.7 NC NC  -- NC 2 2.6 NC NC  -- NC 0 1.1 NC NC  -- NC
Breast 9 15.9 57 26  -- 108 0 0.1 NC NC  -- NC 9 15.8 57 26  -- 108
Colon/Rectum 18 14.1 128 76  -- 202 6 6.7 90 33  -- 196 12 7.4 163 84  -- 284
Gallbladder 1 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.2 NC NC  -- NC
Liver / IBD 1 0.5 NC NC  -- NC 1 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 14 13.6 103 56  -- 173 7 7.8 90 36  -- 186 7 5.8 120 48  -- 248
Melanoma 1 2.2 NC NC  -- NC 1 1.1 NC NC  -- NC 0 1.1 NC NC  -- NC
Non-Hodgkin Lymphoma 2 3.3 NC NC  -- NC 0 1.6 NC NC  -- NC 2 1.7 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 10C 
Cancer Incidence 
Census Tract 6511, New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Bladder 3 3.2 NC NC  -- NC 3 2.3 NC NC  -- NC 0 1 NC NC  -- NC
Breast 16 15.2 105 60  -- 171 0 0.1 NC NC  -- NC 16 15 106 61  -- 173
Colon/Rectum 11 12.2 90 45  -- 162 4 5.8 NC NC  -- NC 7 6.4 110 44  -- 227
Gallbladder 1 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.2 NC NC  -- NC
Liver / IBD 1 0.6 NC NC  -- NC 0 0.4 NC NC  -- NC 1 0.2 NC NC  -- NC
Lung/Bronchus 20 13.5 148 91  -- 229 12 7.2 167 86  -- 291 8 6.3 127 55  -- 251
Melanoma 1 2.5 NC NC  -- NC 0 1.3 NC NC  -- NC 1 1.2 NC NC  -- NC
Non-Hodgkin Lymphoma 5 3.7 137 44  -- 319 4 1.8 NC NC  -- NC 1 1.8 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 10D 
Cancer Incidence 
Census Tract 6511, New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Bladder 1 3 NC NC  -- NC 0 2.1 NC NC  -- NC 1 0.9 NC NC  -- NC
Breast 7 15.4 45 * 18  -- 94 0 0.1 NC NC  -- NC 7 15.3 46 * 18  -- 94
Colon/Rectum 16 11.7 137 78  -- 223 7 5.7 124 50  -- 255 9 6 150 68  -- 284
Gallbladder 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 4 0.9 NC NC  -- NC 2 0.6 NC NC  -- NC 2 0.3 NC NC  -- NC
Lung/Bronchus 17 14.1 120 70  -- 193 9 7.3 124 57  -- 235 8 6.9 117 50  -- 230
Melanoma 1 3.3 NC NC  -- NC 0 1.7 NC NC  -- NC 1 1.5 NC NC  -- NC
Non-Hodgkin Lymphoma 1 3.7 NC NC  -- NC 1 1.9 NC NC  -- NC 0 1.9 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 10E 
Cancer Incidence 
Census Tract 6511, New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.4 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.2 NC NC  -- NC
Bladder 4 2.3 NC NC  -- NC 4 1.6 NC NC  -- NC 0 0.7 NC NC  -- NC
Breast 6 14.8 41 * 15  -- 88 0 0.1 NC NC  -- NC 6 14.7 41 * 15  -- 89
Colon/Rectum 11 10.7 103 51  -- 185 5 5.3 95 31  -- 222 6 5.4 111 41  -- 242
Gallbladder 1 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.2 NC NC  -- NC
Liver / IBD 1 1.2 NC NC  -- NC 0 0.9 NC NC  -- NC 1 0.3 NC NC  -- NC
Lung/Bronchus 8 14.2 56 24  -- 111 6 6.9 86 31  -- 188 2 7.3 NC NC  -- NC
Melanoma 2 4.5 NC NC  -- NC 0 2.4 NC NC  -- NC 2 2.2 NC NC  -- NC
Non-Hodgkin Lymphoma 2 4.0 NC NC  -- NC 1 2.1 NC NC  -- NC 1 2.0 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 11A 
Cancer Incidence 
Census Tract 6515, New Bedford, Massachusetts 
1982-1986 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Bladder 2 3.1 NC NC  -- NC 2 2.2 NC NC  -- NC 0 0.9 NC NC  -- NC
Breast 16 10.8 147 85  -- 241 0 0.1 NC NC  -- NC 16 10.7 149 85  -- 242
Colon/Rectum 10 11.7 86 41  -- 158 3 5.5 NC NC  -- NC 7 6.2 114 46  -- 234
Gallbladder 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.2 NC NC  -- NC
Liver / IBD 0 0.3 NC NC  -- NC 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC
Lung/Bronchus 6 9.7 62 23  -- 135 5 6.2 81 26  -- 190 1 3.5 NC NC  -- NC
Melanoma 1 1.5 NC NC  -- NC 1 0.7 NC NC  -- NC 0 0.8 NC NC  -- NC
Non-Hodgkin Lymphoma 0 2.1 NC NC  -- NC 0 1.0 NC NC  -- NC 0 1.1 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
 
 87 
TABLE 11B 
Cancer Incidence 
Census Tract 6515, New Bedford, Massachusetts 
1987-1991 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 1 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.1 NC NC  -- NC
Bladder 1 3.0 NC NC  -- NC 1 2.2 NC NC  -- NC 0 0.8 NC NC  -- NC
Breast 7 11.8 59 24  -- 122 0 0.1 NC NC  -- NC 7 11.8 60 24  -- 123
Colon/Rectum 14 11.0 128 70  -- 214 8 5.6 142 61  -- 280 6 5.3 113 42  -- 245
Gallbladder 1 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.1 NC NC  -- NC
Liver / IBD 0 0.4 NC NC  -- NC 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC
Lung/Bronchus 9 10.2 88 40  -- 167 5 6.3 79 26  -- 185 4 3.9 NC NC  -- NC
Melanoma 0 1.7 NC NC  -- NC 0 0.9 NC NC  -- NC 0 0.8 NC NC  -- NC
Non-Hodgkin Lymphoma 3 2.5 NC NC  -- NC 1 1.3 NC NC  -- NC 2 1.2 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 11C 
Cancer Incidence 
Census Tract 6515, New Bedford, Massachusetts 
1992-1996 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 1 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 1 0.1 NC NC  -- NC
Bladder 2 2.5 NC NC  -- NC 1 1.8 NC NC  -- NC 1 0.7 NC NC  -- NC
Breast 9 11.5 78 36  -- 148 0 0.1 NC NC  -- NC 9 11.4 79 36  -- 149
Colon/Rectum 10 9.3 108 52  -- 198 4 4.7 NC NC  -- NC 6 4.6 131 48  -- 286
Gallbladder 0 0.2 NC NC  -- NC 0 0.0 NC NC  -- NC 0 0.1 NC NC  -- NC
Liver / IBD 1 0.5 NC NC  -- NC 1 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC
Lung/Bronchus 10 10.1 99 47  -- 182 5 5.7 87 28  -- 203 5 4.3 115 37  -- 269
Melanoma 0 1.9 NC NC  -- NC 0 1.0 NC NC  -- NC 0 0.9 NC NC  -- NC
Non-Hodgkin Lymphoma 1 2.8 NC NC  -- NC 1 1.5 NC NC  -- NC 0 1.3 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 11D 
Cancer Incidence 
Census Tract 6515, New Bedford, Massachusetts 
1997-2001 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Bladder 2 2.2 NC NC  -- NC 1 1.6 NC NC  -- NC 1 0.6 NC NC  -- NC
Breast 12 12.0 100 51  -- 174 0 0.1 NC NC  -- NC 12 12.0 100 52  -- 175
Colon/Rectum 10 8.7 114 55  -- 210 6 4.2 142 52  -- 308 4 4.5 NC NC  -- NC
Gallbladder 0 0.2 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Liver / IBD 2 0.7 NC NC  -- NC 2 0.5 NC NC  -- NC 0 0.2 NC NC  -- NC
Lung/Bronchus 11 10.6 104 52  -- 186 7 5.4 129 52  -- 266 4 5.2 NC NC  -- NC
Melanoma 1 2.5 NC NC  -- NC 1 1.3 NC NC  -- NC 0 1.2 NC NC  -- NC
Non-Hodgkin Lymphoma 8 2.8 283 * 122  -- 559 4 1.4 NC NC  -- NC 4 1.4 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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TABLE 11E 
Cancer Incidence 
Census Tract 6515, New Bedford, Massachusetts 
2002-2006 
Cancer Type
Obs Exp SIR Obs Exp SIR Obs Exp SIR
Other Biliary Tract 0 0.3 NC NC  -- NC 0 0.1 NC NC  -- NC 0 0.1 NC NC  -- NC
Bladder 2 1.7 NC NC  -- NC 1 1.2 NC NC  -- NC 1 0.5 NC NC  -- NC
Breast 11 11.8 93 47  -- 167 0 0.1 NC NC  -- NC 11 11.7 94 47  -- 169
Colon/Rectum 15 8.1 184 * 103  -- 304 6 4.0 152 55  -- 330 9 4.2 215 98  -- 408
Gallbladder 1 0.2 NC NC  -- NC 0 0.0 NC NC  -- NC 1 0.1 NC NC  -- NC
Liver / IBD 1 0.9 NC NC  -- NC 1 0.7 NC NC  -- NC 0 0.3 NC NC  -- NC
Lung/Bronchus 10 10.9 92 44  -- 168 8 5.2 153 66  -- 301 2 5.7 NC NC  -- NC
Melanoma 1 3.5 NC NC  -- NC 1 1.8 NC NC  -- NC 0 1.7 NC NC  -- NC
Non-Hodgkin Lymphoma 2 3.1 NC NC  -- NC 2 1.5 NC NC  -- NC 0 1.5 NC NC  -- NC
Note: SIRs are calculated based on the exact number of expected diagnoses.
Expected number of diagnoses presented are rounded to the nearest tenth.
Obs = Observed number of diagnoses 95% CI = 95% Confidence Interval
Exp = Expected number of diagnoses NC = Not calculated
SIR = Standardized Incidence Ratio * = Statistical significance
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health.
SIRs and 95% CIs are not calculated when the observed number is < 5.
Total Males Females
95% CI 95% CI 95% CI
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New Bedford Blood Serum PCB Testing Program:  PCB Serum Analysis Consent Forms 
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Appendix B 
New Bedford Blood Serum PCB Testing Program: Questions & Answers 
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ICD Codes for Selected Cancer Types 
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ICD CODES FOR SELECTED CANCER TYPES IN THIS REPORT 
 
 
Cancer Site / Type  ICD-O-31 
 Primary Site Codes Histology Type 
Codes2 
Other Biliary Tract C24.0 – C24.9 all except 9590 - 9989 
Urinary Bladder C67.0 - C67.9 all except 9590 - 9989 
Breast C50.0 - C50.9 all except 9590 - 9989 
Colon/Rectum C18.0 - C18.9, C19.9, C20.9, 
C26.0 
all except 9590 - 9989 
Gallbladder C23.9 all except 9590 - 9989 
Liver and Intrahepatic Bile 
Ducts 
C22.0, C22.1 all except 9590 - 9989 
Lung/Bronchus C34.0 - C34.9 all except 9590 - 9989 
Melanoma of Skin C44.0 - C44.9 includes 8720 - 8790 
Non-Hodgkin Lymphoma C00.0 - C80.9 
all sites except C42.0, C42.1, 
C42.4 
includes 9590 - 9595, 
9670 – 9729 
includes 9823, 9827 
 
                                                 
1 International Classification of Diseases for Oncology, 3d Ed. (2) (includes codes added since publication)  
 
2 Only invasive cancers (those with invasive behaviors) are included in this report. 
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Response to Public Comments on 
Public Comment Release, Evaluation of Serum PCB Levels and Cancer Incidence Data, 
Parker Street Waste Site Neighborhood  
 
RESPONSE TO COMMENTS INTRODUCTION 
The PSWS neighborhood report was released as a public comment draft on September 
28, 2011 and a 6-week comment period was established (e.g., through November 9, 2011).  
Comments were received from EPA’s Technical Assistance Services for Communities (TASC) 
program on behalf of Citizens Leading Environmental Action Network Inc. (CLEAN) (n=35) 
and Dr. Robert Herrick, ScD, CIH, of the Harvard School of Public Health’s Department of 
Environmental Health (n=2).  Comments that were similar in nature were grouped together for 
response.   
In addition to responding to comments to this report, where appropriate, MDPH made 
changes to the report to improve clarity or provide more information based on general comments 
made to the BEH report entitled Health Consultation: Evaluation of Indoor Environmental 
Conditions and Potential Health Impacts, New Bedford High School, 230 Hathaway Boulevard, 
New Bedford, MA.  Examples of the types of changes made include: 
 Addition of a glossary 
 Language describing MDPH’s qualitative evaluation of PCB congener patterns 
GENERAL COMMENTS 
Comment: “the comprehensibility of the report would be greatly improved by: (i) the addition of 
a clearly written executive summary, (ii) a glossary defining key scientific and technical 
terms (e.g., 95% confidence interval, congeners, SIRs), (iii) a section giving the basis for 
the various agency guidance values used in the report (e.g., whether the guidance values 
are health-based or technology-based), and (iv) clear graphics summarizing the 
biomonitoring data and providing comparative values such as the NHANES median 
values.” 
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Response: To address this comment, an executive summary, a glossary, and graphs (Figures 4 
through 11) have been added to the report.   
It should be noted that this exact comment was made regarding MDPH’s report 
evaluating the indoor environment at New Bedford High School (NBHS).  Section iii of 
this comment refers to agency guideline values that appear in the NBHS report for 
comparison with indoor environmental samples, such as guidelines provided by the 
Agency for Toxic Substances & Disease Registry (ATSDR).  This report does not include 
a similar evaluation, thus no changes were made to this report. 
 
III. PCB SERUM TESTING 
A. Methods 
 
Comments: “Documentation is not provided to justify that methods used by the MDPH’s 
William A. Hinton State Laboratory Institute (SLI) Division of Analytical Chemistry and 
methods used by the CDC produce comparable results. CLEAN may want to ask MDPH 
if this documentation is available for review.”  “Pg 5, last paragraph: In order to compare 
analytical results between laboratories, it is essential that the labs demonstrate that they 
can produce comparable results. It is unclear what is meant by SLI using “a congener-
specific method similar to the methods used by the U.S. CDC...”.  The method used 
should be defined and the QA/QC process described. Evidence that the lab can produce 
comparable results to CDC (e.g., participation in round robin, etc.) should be provided.” 
Response: The phrase “a congener-specific method” refers to a laboratory method that analyzes 
for individual PCB congeners.  PCBs refer to a class of chemical compounds with 209 
possible congeners in which chlorine atoms have replaced some or all of the hydrogen 
atoms in the biphenyl molecule.   
The following language was added to the Methods section of the report: The 
method for determination of PCB congeners was developed at CDC and transferred to the 
SLI.  The standard operating procedure (SOP AC.012) for determination of PCB 
congeners in human serum details a solvent extraction, silica gel clean-up and dual 
capillary column gas chromatographic analysis with electron capture detection.       
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Quality assurance measures for the method include the analysis of reagent blanks 
that are monitored for contamination and subtracted from the samples in each run; the 
analysis of fortified serum samples, the results of which are plotted on lot & instrument 
specific quality control charts for review to determine compliance with acceptance 
criteria for the batch; and individual sample fortification with surrogate analytes that are 
evaluated for compliance with acceptable recovery criteria.  Other batch specific controls 
include criteria for the calibration curve and internal standard recovery.   
 
Comments: “It is unclear in the health consultation report how PCB levels below the limit of 
detection were handled. CDC assigns a value greater than zero to “nondetect” results. 
CLEAN may want to ask if this study used the same method as the CDC for handling 
PCB levels below the limit of detection.”  “Table 1 and throughout: It is absolutely 
essential that the report clarify how PCB levels below the limit of detection were 
handled. CDC assigns a value of LOD/sq rt 2.  The method used for the New Bedford 
study would have to be the same in order to compare summed PCB levels.”  “Table 4: 
Same issue as noted previously regarding method for assigning values for measurements 
below the limit of detection.” 
Response: The following language was added to the PCB Serum Sampling Methods section of 
the report: To calculate total PCB concentrations, as well as summary statistics such as 
geometric means and percentiles, CDC assigns sample results that were not detected 
above the method’s limit of detection (LOD) a value equal to the LOD divided by square 
root of 2.  New Bedford participants’ individual serum PCB results, as well as summary 
statistics (e.g., geometric means and percentiles) were calculated using this method to be 
comparable to CDC summary data. 
 
Comment: A number of comments suggest that, to be consistent with the Patterson paper that 
reports CDC’s summary of the results of the NHANES serum PCB analyses, MDPH 
should sum dioxin-like congeners detected in serum samples separately (Patterson 2009).   
 Appendix D, page 107 
Response: MDPH’s evaluation of New Bedford participants’ serum PCB levels was conducted 
in a manner that was consistent with the goal of the serum PCB testing offer; to 
determine if residents in the neighborhood of the PSWS had elevated serum PCB levels 
compared to the U.S. population based on comparison with CDC’s reference ranges for 
the general U.S. population. 
New Bedford results were compared with the sum of the 15 most commonly 
detected congeners from NHANES 2003-2004 as provided to MDPH by CDC for this 
purpose.  A total PCB concentration was calculated for each of the New Bedford 
participants by summing the concentrations of the 15 most commonly detected congeners 
following NHANES methodology.  These congeners also include a sub-set of the dioxin-
like congeners (e.g., 105, 118, and 156).  Thus, the approach used by MDPH to calculate 
total PCB concentrations is consistent with CDC’s approach and no revision was made to 
the report. 
 
Comments: “Pg 6: The information on this page will be extremely difficult for anyone not well-
versed in PCB terminology to interpret. If the reader was to turn to the publicly-available 
information in the CDC report, they would not find the summed concentrations of the 
congeners, but rather find tables for each individual congener. No congener-specific data 
are given in the report to justify the selection of the 15 congeners listed.”  “Pg 8, section 
3: The report should clarify the source of the summed NHANES data. The community 
will not be able to find summed data in the National Exposure Report as data are 
congener-specific (not summed). I was unable to find the summed values provided in the 
Health Consultation in Patterson et al.” 
Response: In previous MDPH serum PCB blood sampling efforts, CDC had advised that the 
most appropriate way to compare the data is to take the most common 15 congeners 
identified in NHANES that were also identified in participants and compare those 
congeners.   
New Bedford results were compared with the sum of the 15 most commonly 
detected congeners from NHANES 2003-2004.  These NHANES summary statistics 
were provided to MDPH by CDC to aid in the interpretation of serum PCB results.  No 
revision was made to the report.   
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B. Results and Discussion 
 
Comments: “Pg 7, last paragraph: The description of which residents were included in this 
report versus the separate report is confusing.” 
Response: MDPH revised this paragraph as follows: Out of the 91 participants that consented to 
and submitted blood samples, 42 individuals were current or former residents in the 
neighborhood around the PSWS and three others reported that they had spent a 
significant amount of time at the PSWS (Figure 4).  Participants are included in this 
report if, at the time of the exposure assessment interview, they were among the 42 
individuals living in the neighborhood around the PSWS.  In addition, three other 
individuals that were not residents, but reported spending a significant amount of time at 
the PSWS were included, for a total of 45 participants in the evaluation of PCB serum 
analyzed in relation to outdoor PCB exposure concerns.  As mentioned earlier, results for 
individuals that reported working at NBHS, KMS, or the former KMS (including some 
current and former residents in the neighborhood around the PSWS) are included in the 
separate MDPH report.  Results for individuals that lived in the neighborhood around the 
PSWS and worked at the school are included in both reports. 
 
Comments: “The question I would like to raise is on the method limits of detection for the SLI 
measurements of serum PCB. Page 8 of the report states that no PCBs were detected in 
the serum of the participants aged 12-19 and 20-29. What was the limit of detection for 
these measurements, was it comparable to the CDC lab that did the analysis for the 
NHANES?”  “The report should include detection limits for each congener and compare 
these to CDC’s detection limits. This is especially critical for congeners with a large 
number of measurements below the limit of detection.” 
Response: The MDPH/SLI limits of detection are not as sensitive as those employed by CDC.  
For that reason MDPH asked CDC to evaluate the comparability of SLI’s results to 
CDC’s.  CDC analyzed a subset of the serum samples (split samples).  CDC analyzed 10 
split samples out of the 91 samples collected (>10% of samples collected).  Both the SLI 
and CDC results are presented in the table below.  A comparison of the split sample 
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results indicates that in all cases SLI results were higher than the corresponding CDC 
results by between 0.176 – 0.908 ppb.  SLI’s results are higher due in part to higher 
detection limits.  To calculate total PCB concentrations, CDC assigns sample results that 
were not detected above the method’s limit of detection (LOD) a value equal to the LOD 
divided by square root of 2.  New Bedford participants’ individual serum PCB results 
were calculated using this method to be comparable to CDC’s NHANES data.  The 
results reported by SLI slightly over-estimate total PCB concentrations.  Thus, comparing 
SLI results to NHANES would tend to overestimate any differences between the New 
Bedford results and the levels observed in the general U.S. population.   
Total PCBs Split Sample Results (ppb; Whole Weight) 
No. SLI CDC Difference
1 4.329 4.153 0.176
4 1.276 1.002 0.274
2 1.843 1.568 0.276
3 7.742 7.463 0.279
6 2.469 2.129 0.340
7 2.911 2.545 0.366
5 1.376 0.957 0.418
8 1.053 0.546 0.507
9 0.879 0.310 0.569
10 2.224 1.318 0.907
Notes:
* Total PCBs were calculated by summing the 15 most commonly detected congeners.  If a 
congener was not detected it was assumed to be equal to the limit of detection divided by the 
square root of 2.  Both CDC and MDPH use this method.  
 
The goal of the serum PCB testing offer was to determine if residents in the 
neighborhood of the PSWS had elevated serum PCB levels compared to the U.S. 
population based on comparison with CDC’s reference ranges for the general U.S. 
CDC =
Difference = SLI result (ppb) - CDC result (ppb)
No. =
SLI =
U.S. Centers for Disease Control, National Center for 
Environmental Health, Division of Laboratory Science
Number
Massachusetts Department of Public Health William A. 
Hinton State Laboratory
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population and to determine whether any patterns emerged that suggested exposures 
during a particular time and or in a particular area on or near the PSWS.  MDPH’s 
overestimating of participant levels would tend to exaggerate differences where the 
participant results exceeded typical values for the general population; therefore, MDPH’s 
approach was health protective because any exceedances would be noted and reported as 
such.  No revision was made to the report. 
 
Comments: “Pg 9, section 5, first paragraph: Why is the language “median/50th %” used here 
and throughout? One term should be selected and defined.”  “Pg 10, section 7: This 
section is difficult to understand. Why switch from medians to means to geometric 
means? How is the community to interpret this?” 
Response: The term 50th percentile was used because the report also discusses the 95th 
percentile, based on NHANES terminology; however, the term median, which is the 
same as 50th percentile, is more familiar to most people, and hence MDPH used both 
terms for clarity.   
The median serum PCB levels for each age group were calculated for comparison 
to NHANES median levels used to characterize a population.  Geometric means (another 
statistic used by NHANES for comparison purposes) were calculated by MDPH to 
compare different groups (e.g., comparisons of serum PCBs levels based on years of 
residency).  According to CDC, a geometric mean provides a better estimate of central 
tendency than the arithmetic mean for data that are distributed with a long tail at the 
upper end of the distribution. This type of distribution is common in the measurement of 
environmental chemicals in blood or urine.  No other averaging statistic (e.g., arithmetic 
mean) was used in the evaluation of serum PCB results.  No revision was made to the 
report. 
 
Comments: “It is not clear why the report states that those with serum PCB levels within the 
95th percentile are within “typical” variation in the US population. Why is being in the 
95th percentile “typical” or “usual” when only 5% of the population had higher levels? 
The report would be more objective if it simply noted where along the spectrum of 
national data the New Bedford residents blood levels are; this could be most clearly 
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shown in a graphic.”  “Pg 37, 1st paragraph: I disagree that if a serum PCB level is below 
the 95th % that this is “typical.” It would be more objective to simply note that the levels 
observed for 42 of the participants were below the 95th % and three were above. The 
actual data for individuals in NHANES are accessible and the serum data for the 
individuals with the highest levels could be obtained.” 
Response: As mentioned in the report, the NHANES survey is designed to provide 
biomonitoring data that is representative of the general U.S. population.   
Figures 6 and 7 were added illustrating summary statistics of serum PCB levels 
for the New Bedford participants and NHANES 2003-2004.   Also, the following 
language was added to the Methods section of the report: Due to differences among 
individuals, you would expect to see a range of serum PCB levels in the general 
population.  The range of concentrations reported by NHANES provides health 
professionals with information on the degree of variation that can be expected in the 
general population.  According to the U.S. CDC, the 95th percentile is useful for 
determining whether serum PCB levels are unusual.  Based on this guidance from CDC, 
an individual with serum concentrations above the 50th percentile but below the 95th 
percentile is within the typical level of variation seen in the general U.S. population.  
Thus, MDPH used the 95th percentile value for comparison with the participants’ serum 
PCB results.   
 
Comments: The actual data for individuals in NHANES are accessible and the serum data for 
the individuals with the highest levels could be obtained. It would be of interest to 
determine whether the three New Bedford participants had levels higher than the highest 
NHANES levels.” 
Response: MDPH contacted CDC regarding this question.  According to CDC the New Bedford 
participants did not have levels exceeding the maximum NHANES values or the 
NHANES 99th percentile values for their age groups.  No revision was made to the 
report. 
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Comments: “Pg 10, 2nd paragraph: The data for the residents are not given and so there is no 
way to compare the data to the NHANES data. Please check the other sections of the 
report, as this is not the only section where serum data were not provided.” 
Response: MDPH corrected this error in the report.  The following language was added to the 
section entitled 5) Serum PCB Levels Measured in Participants 40-59 Years Old (existing 
language in italics): The 95th percentile serum PCB level for participants in this age 
group is 2.730 ppb (whole weight) and 568.5 ppb (lipid-adjusted).  The NHANES 95th 
percentile concentration for this age group is 2.780 ppb (whole weight) with a 95% 
confidence interval of 2.307 ppb to 3.663 ppb and 402.2 ppb (lipid-adjusted) with a 95% 
confidence interval of 325.1 to 540.2 ppb.  Therefore, the New Bedford participants’ 95th 
percentile serum PCB levels for lipid-adjusted results in this age group are higher than 
the NHANES 95th percentile for the U.S. population; however, the whole weight results 
were within the NHANES 95th percentile.     
The following language was added to the section entitled 6) Serum PCB Levels 
Measured in Participants 60+ Years Old (existing language in italics): The 95th 
percentile serum PCB level for participants in this age group is 5.015 ppb (whole weight) 
and 698.0 ppb (lipid-adjusted).  The NHANES 95th percentile concentration for this age 
group is 5.123 ppb (whole weight) with a 95% confidence interval of 4.131 ppb to 6.556 
ppb and 769.4 ppb (lipid-adjusted) with a 95% confidence interval of 600.0 to 1026.5 
ppb.  Therefore, the 95th percentile serum PCB levels for the participants, for both whole 
weight and lipid-adjusted results, are within the respective NHANES 95th percentiles for 
the U.S. population.   
 
Comments: “Clarify whether or not differences between serum PCB levels in New Bedford 
residents and the US population are statistically significantly different.”  “Pg 10, section 
7: “…there is no justification given for the mathematical approach to examining the 
effect of years of residence on serum PCB levels. Why arbitrarily split the group into two 
components? Given the number of confounding variables, I would not expect to see any 
useful result using this approach. Why not use a regression to examine the data?” 
Response: Serum PCB sampling was offered as a public service to address 
community concerns about opportunities for exposure to PCBs in the neighborhood 
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around the PSWS.  Thus, the testing offer was not designed as an epidemiological or 
analytical study, where participation, for example, might have been restricted to 
randomly selected residents or might have included matched controls; which would have 
produced a representative sample of the population.  Thus it is more appropriate to use 
CDC methodology to evaluate the results.  Consistent with guidance from the CDC, 
MDPH compared results to the 95th percentile value from the NHANES to determine 
whether serum PCB levels differ from the typical range observed.   
That being said, MDPH was aware that it is important to evaluate any potential 
relationship between length of residency and serum PCB levels.  MDPH took the 
midpoint (or median) of the range of length of residency to compare serum PCB levels in 
two groups (less than or equal to the median years of residency versus more than the 
median years of residency).  As noted in the report, these data did not show a consistent 
pattern of higher serum PCB concentrations with more years of residency, and they 
suggest that residing near the PSWS was not a primary indicator of serum PCB levels.   
 
Comments: “Pg 11, end of section 7: Here and in other places in the report, it is noted that other 
factors contribute to a person’s serum PCB levels. This is correct. What is confusing is 
that data on some of the important variables was apparently collected as part of the 
questionnaire phase of the study. Why were these data not examined? While it can be 
difficult to use questionnaire data on factors such as fish consumption, why collect these 
data and not at least attempt to use them?” 
Response: An exposure assessment questionnaire was administered to all participants of the 
blood serum PCB testing offer.  The exposure assessment questionnaire was designed to 
obtain information on risk factors that are known to or may affect serum PCB levels (e.g., 
age, fish consumption, occupational exposures), as well as information on factors specific 
to residing near the PSWS, such as years of residency.   
The following language was added to the PCB Serum Testing Methods section of 
the report to address this comment: Information collected by this questionnaire was used 
to evaluate serum PCB results.  In particular, information regarding age, place of 
residence, and location and length of residency were evaluated in the report.  Information 
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including diet, other occupational exposures, and specific routes of exposure related to 
the PSWS were also evaluated on an individual level on a case-by-case basis.   
 
Comments: “Pg 12, top: The statement “...serum concentrations for these five individuals 
diagnosed with cancer are within the typical variation in the US population” should be 
removed. The implication is that if one is within the range of concentrations observed in 
the NHANES data, one is not at increased risk for disease. This is most certainly not true. 
One of the well- documented difficulties with interpreting NHANES data has been in 
understanding what the serum (or urine) levels mean in terms of health. For only a very 
few chemicals can we do this type of interpretation. This should be made clear in the 
report.” 
Response: MDPH agrees that not enough is known about how serum PCB levels relate to cancer 
risk; however, the purpose of the section entitled Serum PCB Levels Measured in 
Participants Diagnosed with Cancer is to determine if there is any pattern of higher 
serum PCB levels in participants diagnosed with cancer and the statement referenced in 
the above comment simply conveys the results of this evaluation.  As stated in the report, 
more discussion on the incidence of cancer among New Bedford residents is provided in 
the Cancer Incidence Analysis section of the report.  No revision was made to the report. 
 
Comments: “Pg 37, 2nd paragraph, end: The report does not appear to include a congener-
specific comparison between New Bedford and NHANES so there is no way to 
corroborate this statement.”  “In fact, while the report states that it will provide a 
qualitative comparison of congener patterns in New Bedford residents to the NHANES 
data, it does not do this. So there is neither a quantitative nor qualitative justification for 
congener selection in this report.” 
Response: MDPH added information in the report regarding the qualitative evaluation of 
congener patterns to the Methods and Results sections of the report and has added 
example congener pattern graphs to the Figures section of the report (Figures 8 and 9).   
The additional language added to the Methods section is as follows: For the 
qualitative congener pattern evaluation, MDPH visually compared the distribution of 
percent contribution of the congeners most commonly seen in serum and analyzed by SLI 
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for all New Bedford participants to the percent contribution of these congeners for all 
ages from the NHANES data.  In addition, a subset of sample results was submitted to 
CDC for review to confirm that individual differences noted were within the range 
typically seen.   
The additional language in the Results section is as follows: In this report, data 
have been provided on total PCBs based on summing the most frequently detected 15 
congeners.  Figure 8 shows the distribution of percent contribution of the 35 congeners 
most commonly seen in serum and analyzed by SLI for all New Bedford participants.  
Percent contributions are also provided in Figure 9 for all ages from the NHANES data.  
The congener patterns observed in New Bedford and NHANES are similar, suggesting 
similarities with what is found in the U.S. population.  In addition, individual congener 
patterns were reviewed and a subset of sample results was submitted to CDC for review 
to confirm that individual differences noted were within the range typically seen.  CDC 
identified one individual’s congener pattern as atypical and MDPH sent a letter to this 
individual communicating this information.  CDC noted that the congener patterns of the 
majority of New Bedford participants appeared to be typical, suggesting that exposure in 
the majority of the New Bedford participants appeared similar to that of the general U.S. 
population.   
 
IV. CANCER INCIDENCE ANALYSIS 
A. Methods 
 
Comments: Pg 12, top: “… it is stated that the five different cancer types are not associated with 
PCB exposure. Please include the five cancer types. In addition, the “epidemiological 
literature” should be cited.”   
Response: MDPH cannot disclose the cancer diagnoses of the five serum PCB testing offer 
participants due to privacy laws.  No revision was made to the report. 
 
Comments: “Pg 12, section IV, second paragraph: What are the nine cancers? Which of these 
were of concern to the community because of suspected elevations (I don’t believe that 
this is ever spelled out in the report)? These should be listed here.”   
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Response: This section provides an overview of the cancer incidence analysis.  In subsequent 
subsections, more details are provided, including a discussion of the nine types of cancer 
evaluated.  As requested, the nine types of cancer have been added to the introductory 
discussion on p.15. 
“The types of cancer evaluated include the following: cancers of the biliary tract, 
bladder, breast, colon/rectum, gallbladder, liver/intrahepatic bile duct (IBD), and lung 
and bronchus as well as melanoma and non-Hodgkin lymphoma.  Concerns about the 
occurrence of cancer in the PSWS neighborhood and the New Bedford High School have 
been shared by current and former staff at the high school, by PSWS neighbors, and by 
members of CLEAN.  A range of various types of cancer have been mentioned of 
concern, including some of the cancer types potentially associated with exposure to PCBs 
(such as breast cancer and non-Hodgkin lymphoma) as well as other types of cancer for 
which there is no reported association with PCBs (such as cervical and ovarian cancers). 
For this report, MDPH evaluated those nine types of cancer that have been identified in 
the medical and epidemiological literature as possibly being associated with exposure to 
PCBs.  If exposure to PCBs at the PSWS has resulted in an increased incidence of cancer 
in the neighborhood, it is important to focus the evaluation on those types of cancer 
associated with PCB exposure.”  (This discussion has been added to the report text.)  
Evaluating types of cancer for which no association with PCB exposure has been 
shown or is suspected would not address the questions raised by New Bedford residents 
and NBHS employees.  As discussed in our report, each type of cancer is its own disease 
with its own set of risk factors.  Grouping all cancers together or including those types of 
cancer not associated with PCB exposure in the MDPH evaluation would not be 
informative and would be misleading.  
 
Comments: “Pg 14, top: This discussion is crucial for communicating to the residents why 
certain cancers were investigated while others were not. Rather than simply giving a list 
of cancers investigated, the report should describe the weight-of-evidence for association 
of these cancers with PCB exposure (as is done, for example, in the ATSDR report that is 
cited). This does not have to be extremely lengthy, but can at least summarize the 
confidence that the scientific community has in the data. For example, ATSDR calls the 
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evidence for association between breast cancer and PCB exposure controversial and 
inconclusive. This kind of information is crucial to interpreting the cancer cluster 
results.” 
Response: In ATSDR’s Toxicological Profile for Polychlorinated Biphenyls (ATSDR 2000), it 
summarizes its extensive review of approximately 1,800 human and animal studies that 
have been conducted to evaluate the potential for exposure to PCBs to cause cancer. It 
concludes the following: 
“Based on indications of PCB-related cancer at several sites, particularly the liver, 
biliary tract, intestines, and skin (melanoma), the human studies provide 
suggestive evidence that PCBs are carcinogenic. There is unequivocal evidence 
that PCBs are hepatocarcinogenic in animals.” 
MDPH included these four types of cancer in its evaluation as well as five 
additional types of cancer for which the evidence of an association with PCB exposure is 
not as strong.  These include: non-Hodgkin lymphoma and breast, lung, gallbladder, and 
bladder cancers.  In addition to reviewing the findings of ATSDR’s Toxicological Profile 
for PCBs, a report of approximately 870 pages, MDPH also reviewed the evaluations of 
other cancer epidemiology experts on the types of cancer potentially associated with 
exposure to PCBs, particularly those reported in Cancer Epidemiology and Prevention, a 
comprehensive book on what is known about the risk factors and causes of a wide variety 
of cancers, including those associated with exposure to PCBs.  In Cancer Epidemiology 
and Prevention, the authors report liver and biliary tract cancers as well as melanoma and 
non-Hodgkin lymphoma as types of cancer with evidence of an association with PCB 
exposure.  As previously stated, MDPH evaluated these four types of cancer in our 
report. (This information has been added to the report text.) 
The body of scientific literature on the carcinogenic potential of PCBs is huge and 
new studies continue to be published. It is beyond the scope of this report to discuss in 
detail the scientific weight of the evidence on the carcinogenicity of PCBs by individual 
cancer type. Rather, MDPH relied on the results of peer review panels and cancer 
epidemiology experts who have issued scientifically sound assessments on the 
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epidemiology and carcinogenic potential of PCBs. What is most important to point out is 
that MDPH evaluated in the New Bedford population nine different types of cancer 
potentially associated with PCB exposure, including those with the strongest evidence 
and those with weaker evidence. 
 
Comments: “Pg 16, 2nd paragraph: “Instability” should be defined here. Two paragraphs down, 
“population structure” should be defined.”   
Response: The following language was added to the body of the report and glossary to address 
this comment: Stability in the context of an SIR refers to how the SIR changes when 
there are small increases or decreases in the observed or expected number of cases.  Two 
SIRs may have the same size but not the same stability.  For example, an SIR of 150 may 
represent 6 observed diagnoses and 4 expected diagnoses, or 600 observed diagnoses and 
400 expected diagnoses.  (The SIR is the ratio of the number of observed diagnoses to the 
number of expected diagnoses multiplied by 100.  For example, six divided by 4 equals 
1.5 as does 600 divided by 400; 1.5 multiplied by 100 equals 150.)  Both SIRs represent a 
50 percent excess of observed diagnoses.  However, in the first instance, one or two 
fewer diagnoses would change the SIR a great deal, whereas in the second instance, even 
if there were several fewer diagnoses, the SIR would only change minimally.  When the 
observed and expected numbers of diagnoses are relatively small, their ratio is easily 
affected by one or two diagnoses.  Conversely, when the observed and expected numbers 
of diagnoses are relatively large, the value of the SIR is stable. 
Population structure, in the context of the calculation of an SIR, simply refers to 
the age and gender breakdowns (or distributions) within the New Bedford and 
Massachusetts populations.  Because cancer is a disease greatly affected by age, and also 
by gender, it is very important to account for the ages of people in the populations being 
studied and the numbers of males versus females.  This process of accounting for 
differences in the ages of two populations is referred to as age adjustment or age 
standardization. 
 
VI. CONCLUSIONS 
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Comments: “The report states that BEH undertook " ... to determine levels of PCBs in blood 
serum and whether patterns might exist to suggest that residence and/or occupation or 
attendance at the schools played a primary role in PCB exposures." In my opinion, while 
the investigation determined the levels of 15 PCB congeners among the study subjects, 
this approach was not sufficient to examine the possible role of PCB exposure resulting 
from residence, occupation or attendance at the schools.” 
“Specifically, the selection of the 15 most abundant congeners normally found in 
human serum (PCBs 52, 74, 99, 105, 118, 138/158, 146, 153, 156, 170, 180, 187, 194, 
199, and 204) seriously limits the interpretability of the findings, and makes it very 
unlikely that the role of residence, occupation or attendance at the schools can be 
characterized. Several investigators have proposed sets of PCB congeners in serum that 
may be considered markers of exposure from environmental sources, as opposed to 
dietary sources. These congeners include PCB 6, 8, 16, 18, 25, 26, 28, 
31,33,37,41,44,47,49, 52,60, 66, 70, 84, 90/101, 97, 110, and 136. This list is compiled 
from the publications cited below. For example, De Caprio et.al studied a group of 
Akwesasne Mohawks with historical PCB exposure from diet, as well as environmental 
sources. He concluded that congeners 8, 18, 32/16, 31, 28, 33, 52, 44, 70, 66, 95, and 
90/101 (primarily tri- and tetrachloro PCBs) reflected recent inhalation exposure. Freels 
et.al suggested that combinations of congener levels and their relative proportions should 
be considered relevant in tracking the source and route of PCB exposures.” 
“So while the BEH has shown that the serum PCB levels in the subjects are 
comparable to the NHANES levels, the conclusion that PCB congener patterns are 
consistent with what is typically seen in the U.S. population, suggestive of dietary 
sources, is unfounded. With the exception of PCB 52, the BEH did not measure the PCB 
congeners that have been identified as coming for non-dietary sources of exposure.” 
Response: MDPH’s serum PCB testing offer was designed as a public service and was 
conducted in a manner consistent with methods used by CDC to evaluate serum PCB data 
on a national level.  The DeCaprio et. al. article mentioned by the commenter describes 
hypothesis-generating research that requires additional research studies for confirmation.  
MDPH relied primarily on established methods of evaluation currently used by public 
health experts to ensure valid results.   
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It should be noted that in response to other submitted comments, MDPH added 
language to the report providing additional details regarding evaluation methods; 
specifically, MDPH’s qualitative evaluation of congener patterns.  As described in the 
new language, congener patterns were evaluated by examining the percent contribution of 
35 congeners.  This is also similar to the method described by the commenter from the 
Freels et. al. paper as being relevant to tracking the source and route of PCB exposures.  
In addition, a number of the congeners identified by the commenter as possible markers 
of environmental exposure or as possibly reflecting recent exposure were included in the 
qualitative evaluation, including congeners 28, 44, 49, 52, 66, 101, and 110.   
In addition to MDPH’s congener pattern evaluation, a subset of sample results 
was submitted to CDC for review to confirm that individual differences noted were 
within the range typically seen.  CDC identified one atypical pattern, but noted that the 
congener patterns of the majority of New Bedford participants appeared to be typical.  
The results of this evaluation suggests that exposure in the majority of the New Bedford 
participants appeared similar to that of the general U.S. population, thus MDPH believes 
that its evaluation supports the report conclusions.  No revisions to the report were made. 
 
TABLES 
Comments: “Table 2: I think this is a mistake – the parentheticals are 95% CIs, not 50th 
percentiles. Footnote: same comment as in Table 1.” 
Response: The footnotes for Tables 1 and 2 were revised for clarity as follows:  
 
“2. The range of serum PCB levels detected is presented in parentheses below the median for 
New Bedford residents.”   
 
“3. The 95% confidence intervals appear in parentheses below both the NHANES median and 
95th percentile values.  The 95% CIs presented represent the range of estimated values that have 
a 95% probability of including the true value for the population.” 
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APPENDICES 
Comments: “Appendix B, answer to question 2: What serum PCB level would “raise immediate 
health concerns”? This should be clearly stated.” 
Response: MDPH's past practice has been to contact someone if their serum PCB level was 
significantly higher than the 99th percentile (for the age group of the individual involved) 
reported by CDC at the time of the analysis for the general US population.  Such an 
exceedance would warrant a more immediate need for the health care provider to 
consider in their typical course of treatment for their patient.   
  
 
 
 
 
 
 
 
Appendix E 
Glossary of Environmental Health Terms1
                                                 
1 Terms and definitions included in this glossary are primarily from the U.S. Agency for Toxic 
Substance and Disease Registry’s 2005 Public Health Assessment Manual with some additional 
terms and definitions added by MDPH. 
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Glossary of Terms 
 
This glossary defines words used in communications with the public. It is not a complete 
dictionary of environmental health terms. If you have questions or comments, call MDPH/BEH 
at 617-624-5757. 
 
General Terms 
 
50th percentile  
The 50th percentile is also known as the median.  The midpoint of a group of observations when 
they are arranged in order from lowest to highest. 
 
95th percentile  
The serum PCB level below which 95% of the levels measured in NHANES participants are 
found. 
 
95% confidence interval 
The 95% confidence interval is a range of estimated values that have a 95% probability of 
including the true value for the population.   
 
Absorption  
The process of taking in. For a person or an animal, absorption is the process of a substance 
getting into the body through the eyes, skin, stomach, intestines, or lungs.  
 
Acute  
Occurring over a short time [compare with chronic].  
 
Acute exposure  
Contact with a substance that occurs once or for only a short time (up to 14 days) [compare with 
intermediate duration exposure and chronic exposure].  
 
Additive effect  
A biologic response to exposure to multiple substances that equals the sum of responses of all the 
individual substances added together [compare with antagonistic effect and synergistic effect].  
 
Adverse health effect  
A change in body function or cell structure that might lead to disease or health problems  
 
Aerobic  
Requiring oxygen [compare with anaerobic].  
 
Ambient  
Surrounding (for example, ambient air).  
 
Anaerobic  
Requiring the absence of oxygen [compare with aerobic].  
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Analyte  
A substance measured in the laboratory. A chemical for which a sample (such as water, air, or 
blood) is tested in a laboratory. For example, if the analyte is mercury, the laboratory test will 
determine the amount of mercury in the sample.  
 
Analytic epidemiologic study  
A study that evaluates the association between exposure to hazardous substances and disease by 
testing scientific hypotheses.  
 
Antagonistic effect  
A biologic response to exposure to multiple substances that is less than would be expected if the 
known effects of the individual substances were added together [compare with additive effect 
and synergistic effect].  
 
Aroclor  
PCBs were commercially produced and sold in the U.S. as mixtures called Aroclors. 
 
Background level  
An average or expected amount of a substance or radioactive material in a specific environment, 
or typical amounts of substances that occur naturally in an environment.  
 
Biodegradation  
Decomposition or breakdown of a substance through the action of microorganisms (such as 
bacteria or fungi) or other natural physical processes (such as sunlight).  
 
Biologic indicators of exposure study  
A study that uses (a) biomedical testing or (b) the measurement of a substance [an analyte], its 
metabolite, or another marker of exposure in human body fluids or tissues to confirm human 
exposure to a hazardous substance [also see exposure investigation].  
 
Biologic monitoring  
Measuring hazardous substances in biologic materials (such as blood, hair, urine, or breath) to 
determine whether exposure has occurred. A blood test for lead is an example of biologic 
monitoring.  
 
Biologic uptake  
The transfer of substances from the environment to plants, animals, and humans.  
 
Biomedical testing  
Testing of persons to find out whether a change in a body function might have occurred because 
of exposure to a hazardous substance.  
 
Biota  
Plants and animals in an environment. Some of these plants and animals might be sources of 
food, clothing, or medicines for people.  
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Body burden  
The total amount of a substance in the body. Some substances build up in the body because they 
are stored in fat or bone or because they leave the body very slowly.  
 
CAP [see Community Assessment Program.]  
 
Cancer  
Any one of a group of diseases that occur when cells in the body become abnormal and grow or 
multiply out of control.  
 
Cancer risk  
A theoretical risk for getting cancer if exposed to a substance every day for 70 years (a lifetime 
exposure). The true risk might be lower.  
 
Carcinogen  
A substance that causes cancer.  
 
Case study  
A medical or epidemiologic evaluation of one person or a small group of people to gather 
information about specific health conditions and past exposures.  
 
Case-control study  
A study that compares exposures of people who have a disease or condition (cases) with people 
who do not have the disease or condition (controls). Exposures that are more common among the 
cases may be considered as possible risk factors for the disease.  
 
CAS registry number  
A unique number assigned to a substance or mixture by the American Chemical Society 
Abstracts Service. 
 
Central nervous system  
The part of the nervous system that consists of the brain and the spinal cord.  
 
CERCLA [see Comprehensive Environmental Response, Compensation, and Liability Act 
of 1980]  
 
Chronic  
Occurring over a long time [compare with acute].  
 
Chronic exposure  
Contact with a substance that occurs over a long time (more than 1 year) [compare with acute 
exposure and intermediate duration exposure]  
 
Cluster investigation 
A review of an unusual number, real or perceived, of health events (for example, reports of 
cancer) grouped together in time and location. Cluster investigations are designed to confirm 
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case reports; determine whether they represent an unusual disease occurrence; and, if possible, 
explore possible causes and contributing environmental factors.  
 
Community Assessment Program (CAP)  
The Community Assessment Program (CAP) is a program within the Bureau of Environmental 
Health at the Massachusetts Department of Public Health.  CAP is tasked with responding to 
concerns about disease patterns, evaluating the frequency and pattern of disease in populations, 
and assessing possible associations between environmental exposures and disease. 
 
Comparison value (CV)  
Calculated concentration of a substance in air, water, food, or soil that is unlikely to cause 
harmful (adverse) health effects in exposed people. The CV is used as a screening level during 
the public health assessment process. Substances found in amounts greater than their CVs might 
be selected for further evaluation in the public health assessment process.  
 
Completed exposure pathway [see exposure pathway].  
 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 
(CERCLA)  
CERCLA, also known as Superfund, is the federal law that concerns the removal or cleanup of 
hazardous substances in the environment and at hazardous waste sites. ATSDR, which was 
created by CERCLA, is responsible for assessing health issues and supporting public health 
activities related to hazardous waste sites or other environmental releases of hazardous 
substances. This law was later amended by the Superfund Amendments and Reauthorization Act 
(SARA). 
 
Concentration  
The amount of a substance present in a certain amount of soil, water, air, food, blood, hair, urine, 
breath, or any other media.  
 
Congener, PCB  
PCB molecules vary in how much chlorine they contain.  Individual unique chlorinated biphenyl 
compounds are known as congeners and there are 209 possible congeners depending on number 
and location of chlorine atoms on the molecule.  Note, the chlorine in PCBs is unrelated to the 
type of chlorine used in pools.  
 
Contaminant  
A substance that is either present in an environment where it does not belong or is present at 
levels that might cause harmful (adverse) health effects.  
 
Delayed health effect  
A disease or an injury that happens as a result of exposures that might have occurred in the past.  
 
Dermal  
Referring to the skin. For example, dermal absorption means passing through the skin.  
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Dermal contact  
Contact with (touching) the skin [see route of exposure].  
 
Descriptive epidemiology  
The study of the amount and distribution of a disease in a specified population by person, place, 
and time.  
 
Detection limit  
The lowest concentration of a chemical that can reliably be distinguished from a zero 
concentration.  
 
Disease prevention  
Measures used to prevent a disease or reduce its severity.  
 
Disease registry  
A system of ongoing registration of all cases of a particular disease or health condition in a 
defined population.  
 
DOD  
United States Department of Defense.  
 
DOE  
United States Department of Energy.  
 
Dose (for chemicals that are not radioactive)  
The amount of a substance to which a person is exposed over some time period. Dose is a 
measurement of exposure. Dose is often expressed as milligram (amount) per kilogram (a 
measure of body weight) per day (a measure of time) when people eat or drink contaminated 
water, food, or soil. In general, the greater the dose, the greater the likelihood of an effect. An 
"exposure dose" is how much of a substance is encountered in the environment. An "absorbed 
dose" is the amount of a substance that actually got into the body through the eyes, skin, 
stomach, intestines, or lungs.  
 
Dose (for radioactive chemicals)  
The radiation dose is the amount of energy from radiation that is actually absorbed by the body. 
This is not the same as measurements of the amount of radiation in the environment.  
 
Dose-response relationship  
The relationship between the amount of exposure [dose] to a substance and the resulting changes 
in body function or health (response).  
 
Environmental media  
Soil, water, air, biota (plants and animals), or any other parts of the environment that can contain 
contaminants.  
 
Environmental media and transport mechanism  
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Environmental media include water, air, soil, and biota (plants and animals). Transport 
mechanisms move contaminants from the source to points where human exposure can occur. The 
environmental media and transport mechanism is the second part of an exposure pathway.  
 
EPA  
United States Environmental Protection Agency.  
 
Epidemiologic surveillance [see Public health surveillance]. 
 
Epidemiology  
The study of the distribution and determinants of disease or health status in a population; the 
study of the occurrence and causes of health effects in humans.  
 
Exposure  
Contact with a substance by swallowing, breathing, or touching the skin or eyes. Exposure may 
be short-term [acute exposure], of intermediate duration, or long-term [chronic exposure].  
 
Exposure assessment  
The process of finding out how people come into contact with a hazardous substance, how often 
and for how long they are in contact with the substance, and how much of the substance they are 
in contact with.  
 
Exposure-dose reconstruction  
A method of estimating the amount of people's past exposure to hazardous substances. Computer 
and approximation methods are used when past information is limited, not available, or missing.  
 
Exposure investigation  
The collection and analysis of site-specific information and biologic tests (when appropriate) to 
determine whether people have been exposed to hazardous substances.  
 
Exposure pathway  
The route a substance takes from its source (where it began) to its end point (where it ends), and 
how people can come into contact with (or get exposed to) it. An exposure pathway has five 
parts: a source of contamination (such as an abandoned business); an environmental media and 
transport mechanism (such as movement through groundwater); a point of exposure (such as a 
private well); a route of exposure (eating, drinking, breathing, or touching), and a receptor 
population (people potentially or actually exposed). When all five parts are present, the exposure 
pathway is termed a completed exposure pathway.  
 
Exposure registry  
A system of ongoing follow-up of people who have had documented environmental exposures.  
 
Feasibility study  
A study by EPA to determine the best way to clean up environmental contamination. A number 
of factors are considered, including health risk, costs, and what methods will work well.  
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Geographic information system (GIS)  
A mapping system that uses computers to collect, store, manipulate, analyze, and display data. 
For example, GIS can show the concentration of a contaminant within a community in relation to 
points of reference such as streets and homes.  
 
Grand rounds  
Training sessions for physicians and other health care providers about health topics.  
 
Groundwater  
Water beneath the earth's surface in the spaces between soil particles and between rock surfaces 
[compare with surface water].  
 
Half-life (t½)  
The time it takes for half the original amount of a substance to disappear. In the environment, the 
half-life is the time it takes for half the original amount of a substance to disappear when it is 
changed to another chemical by bacteria, fungi, sunlight, or other chemical processes. In the 
human body, the half-life is the time it takes for half the original amount of the substance to 
disappear, either by being changed to another substance or by leaving the body. In the case of 
radioactive material, the half life is the amount of time necessary for one half the initial number 
of radioactive atoms to change or transform into another atom (that is normally not radioactive). 
After two half lives, 25% of the original number of radioactive atoms remain.  
 
Hazard  
A source of potential harm from past, current, or future exposures.  
 
Hazardous Substance Release and Health Effects Database (HazDat)  
The scientific and administrative database system developed by ATSDR to manage data 
collection, retrieval, and analysis of site-specific information on hazardous substances, 
community health concerns, and public health activities.  
 
Hazardous waste  
Potentially harmful substances that have been released or discarded into the environment.  
 
Health consultation  
A review of available information or collection of new data to respond to a specific health 
question or request for information about a potential environmental hazard. Health consultations 
are focused on a specific exposure issue. Health consultations are therefore more limited than a 
public health assessment, which reviews the exposure potential of each pathway and chemical 
[compare with public health assessment].  
 
Health education  
Programs designed with a community to help it know about health risks and how to reduce these 
risks.  
 
Health investigation  
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The collection and evaluation of information about the health of community residents. This 
information is used to describe or count the occurrence of a disease, symptom, or clinical 
measure and to evaluate the possible association between the occurrence and exposure to 
hazardous substances.  
 
Health promotion  
The process of enabling people to increase control over, and to improve, their health.  
 
Health statistics review  
The analysis of existing health information (i.e., from death certificates, birth defects registries, 
and cancer registries) to determine if there is excess disease in a specific population, geographic 
area, and time period. A health statistics review is a descriptive epidemiologic study.  
 
Homologue, PCB  
PCB congeners that are organized into groups according to similar numbers of chlorine atoms 
(e.g., dichlorobiphenyls, trichlorobiphenyls, etc.) are called homologues. 
 
Indeterminate public health hazard  
The category used in ATSDR's public health assessment documents when a professional 
judgment about the level of health hazard cannot be made because information critical to such a 
decision is lacking.  
 
Incidence  
The number of new cases of disease in a defined population over a specific time period [contrast 
with prevalence].  
 
Ingestion  
The act of swallowing something through eating, drinking, or mouthing objects. A hazardous 
substance can enter the body this way [see route of exposure].  
 
Inhalation  
The act of breathing. A hazardous substance can enter the body this way [see route of exposure].  
 
Intermediate duration exposure  
Contact with a substance that occurs for more than 14 days and less than a year [compare with 
acute exposure and chronic exposure].  
 
In vitro  
In an artificial environment outside a living organism or body. For example, some toxicity 
testing is done on cell cultures or slices of tissue grown in the laboratory, rather than on a living 
animal [compare with in vivo].  
 
In vivo  
Within a living organism or body. For example, some toxicity testing is done on whole animals, 
such as rats or mice [compare with in vitro].  
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Lowest-observed-adverse-effect level (LOAEL)  
The lowest tested dose of a substance that has been reported to cause harmful (adverse) health 
effects in people or animals.  
 
Median 
The median is also known as the 50th percentile value.  The midpoint of the a group of 
observations when they are arranged in order from lowest to highest 
 
Medical monitoring  
A set of medical tests and physical exams specifically designed to evaluate whether an 
individual's exposure could negatively affect that person's health.  
 
Metabolism  
The conversion or breakdown of a substance from one form to another by a living organism.  
 
Metabolite  
Any product of metabolism.  
 
mg/kg  
Milligram per kilogram.  
 
mg/cm2  
Milligram per square centimeter (of a surface).  
 
mg/m3  
Milligram per cubic meter; a measure of the concentration of a chemical in a known volume (a 
cubic meter) of air, soil, or water.  
 
Migration  
Moving from one location to another.  
 
Minimal risk level (MRL)  
An ATSDR estimate of daily human exposure to a hazardous substance at or below which that 
substance is unlikely to pose a measurable risk of harmful (adverse), noncancerous effects. 
MRLs are calculated for a route of exposure (inhalation or oral) over a specified time period 
(acute, intermediate, or chronic). MRLs should not be used as predictors of harmful (adverse) 
health effects [see reference dose].  
 
Morbidity  
State of being ill or diseased. Morbidity is the occurrence of a disease or condition that alters 
health and quality of life.  
 
Mortality  
Death. Usually the cause (a specific disease, a condition, or an injury) is stated.  
 
Mutagen  
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A substance that causes mutations (genetic damage).  
 
Mutation  
A change (damage) to the DNA, genes, or chromosomes of living organisms.  
 
National Priorities List for Uncontrolled Hazardous Waste Sites (National Priorities List or 
NPL)  
EPA's list of the most serious uncontrolled or abandoned hazardous waste sites in the United 
States. The NPL is updated on a regular basis. 
 
National Toxicology Program (NTP) 
Part of the Department of Health and Human Services. NTP develops and carries out tests to 
predict whether a chemical will cause harm to humans.  
 
No apparent public health hazard  
A category used in ATSDR's public health assessments for sites where human exposure to 
contaminated media might be occurring, might have occurred in the past, or might occur in the 
future, but where the exposure is not expected to cause any harmful health effects.  
 
No-observed-adverse-effect level (NOAEL)  
The highest tested dose of a substance that has been reported to have no harmful (adverse) health 
effects on people or animals.  
 
No public health hazard  
A category used in ATSDR's public health assessment documents for sites where people have 
never and will never come into contact with harmful amounts of site-related substances.  
 
NPL [see National Priorities List for Uncontrolled Hazardous Waste Sites] 
 
PCBs 
Polychlorinated biphenyls (PCBs) refer to a class of chemical compounds with 209 possible 
congeners in which chlorine atoms have replaced some or all of the hydrogen atoms in the 
biphenyl molecule.  PCBs are generally odorless and colorless, very heat stable and fire resistant, 
non-conductive and virtually insoluble in water.  PCBs were historically used in electrical 
components (e.g. capacitors) and in building materials (e.g. caulking), among other uses.   
 
PCB congener  
PCB molecules vary in how much chlorine they contain.  Individual unique chlorinated biphenyl 
compounds are known as congeners and there are 209 possible congeners depending on number 
and location of chlorine atoms on the molecule.  Note, the chlorine in PCBs is unrelated to the 
type of chlorine used in pools.  
 
PCB homologue  
Congeners that are organized into groups according to similar numbers of chlorine atoms (e.g., 
dichlorobiphenyls, trichlorobiphenyls, etc.) are called homologues.   
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Physiologically based pharmacokinetic model (PBPK model)  
A computer model that describes what happens to a chemical in the body. This model describes 
how the chemical gets into the body, where it goes in the body, how it is changed by the body, 
and how it leaves the body.  
 
Pica  
A craving to eat nonfood items, such as dirt, paint chips, and clay. Some children exhibit pica-
related behavior.  
 
Plume  
A volume of a substance that moves from its source to places farther away from the source. 
Plumes can be described by the volume of air or water they occupy and the direction they move. 
For example, a plume can be a column of smoke from a chimney or a substance moving with 
groundwater.  
 
Point of exposure  
The place where someone can come into contact with a substance present in the environment 
[see exposure pathway].  
 
Population  
A group or number of people living within a specified area or sharing similar characteristics 
(such as occupation or age).  
 
Population structure 
Population structure, in the context of the calculation of an SIR, simply refers to the age and 
gender breakdowns (or distributions) within the New Bedford and Massachusetts populations.  
Because cancer is a disease greatly affected by age, and also by gender, it is very important to 
account for the ages of people in the populations being studied and the numbers of males versus 
females.  This process of accounting for differences in the ages of two populations is referred to 
as age adjustment or age standardization. 
 
Potentially responsible party (PRP)  
A company, government, or person legally responsible for cleaning up the pollution at a 
hazardous waste site under Superfund. There may be more than one PRP for a particular site.  
 
ppb  
Parts per billion.  
 
ppm  
Parts per million.  
 
Prevalence  
The number of existing disease cases in a defined population during a specific time period 
[contrast with incidence].  
 
Prevalence survey  
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The measure of the current level of disease(s) or symptoms and exposures through a 
questionnaire that collects self-reported information from a defined population.  
 
Prevention  
Actions that reduce exposure or other risks, keep people from getting sick, or keep disease from 
getting worse.  
 
Public availability session  
An informal, drop-by meeting at which community members can meet one-on-one with ATSDR 
staff members to discuss health and site-related concerns. 
 
Public comment period  
An opportunity for the public to comment on agency findings or proposed activities contained in 
draft reports or documents. The public comment period is a limited time period during which 
comments will be accepted.  
 
Public health action  
A list of steps to protect public health.  
 
Public health advisory  
A statement made by ATSDR to EPA or a state regulatory agency that a release of hazardous 
substances poses an immediate threat to human health. The advisory includes recommended 
measures to reduce exposure and reduce the threat to human health.  
 
Public health assessment (PHA)  
An ATSDR document that examines hazardous substances, health outcomes, and community 
concerns at a hazardous waste site to determine whether people could be harmed from coming 
into contact with those substances. The PHA also lists actions that need to be taken to protect 
public health [compare with health consultation].  
 
Public health hazard  
A category used in ATSDR's public health assessments for sites that pose a public health hazard 
because of long-term exposures (greater than 1 year) to sufficiently high levels of hazardous 
substances or radionuclides that could result in harmful health effects.  
 
Public health hazard categories  
Public health hazard categories are statements about whether people could be harmed by 
conditions present at the site in the past, present, or future. One or more hazard categories might 
be appropriate for each site. The five public health hazard categories are no public health hazard, 
no apparent public health hazard, indeterminate public health hazard, public health hazard, and 
urgent public health hazard.  
 
Public health statement 
The first chapter of an ATSDR toxicological profile. The public health statement is a summary 
written in words that are easy to understand. The public health statement explains how people 
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might be exposed to a specific substance and describes the known health effects of that 
substance.  
 
Public health surveillance 
The ongoing, systematic collection, analysis, and interpretation of health data. This activity also 
involves timely dissemination of the data and use for public health programs. 
 
Public meeting  
A public forum with community members for communication about a site.  
 
Radioisotope  
An unstable or radioactive isotope (form) of an element that can change into another element by 
giving off radiation.  
 
Radionuclide  
Any radioactive isotope (form) of any element.  
 
RCRA [see Resource Conservation and Recovery Act (1976, 1984)]  
 
Receptor population  
People who could come into contact with hazardous substances [see exposure pathway].  
 
Reference dose (RfD)  
An EPA estimate, with uncertainty or safety factors built in, of the daily lifetime dose of a 
substance that is unlikely to cause harm in humans.  
 
Registry  
A systematic collection of information on persons exposed to a specific substance or having 
specific diseases [see exposure registry and disease registry].  
 
Remedial investigation  
The CERCLA process of determining the type and extent of hazardous material contamination at 
a site.  
 
Resource Conservation and Recovery Act (1976, 1984) (RCRA) 
This Act regulates management and disposal of hazardous wastes currently generated, treated, 
stored, disposed of, or distributed.  
 
RFA  
RCRA Facility Assessment. An assessment required by RCRA to identify potential and actual 
releases of hazardous chemicals.  
 
RfD [see reference dose] 
 
Risk  
The probability that something will cause injury or harm.  
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Risk reduction  
Actions that can decrease the likelihood that individuals, groups, or communities will experience 
disease or other health conditions.  
 
Risk communication  
The exchange of information to increase understanding of health risks.  
 
Route of exposure  
The way people come into contact with a hazardous substance. Three routes of exposure are 
breathing [inhalation], eating or drinking [ingestion], or contact with the skin [dermal contact].  
 
Safety factor [see uncertainty factor]  
 
SARA [see Superfund Amendments and Reauthorization Act]  
 
Sample  
A portion or piece of a whole. A selected subset of a population or subset of whatever is being 
studied. For example, in a study of people the sample is a number of people chosen from a larger 
population [see population]. An environmental sample (for example, a small amount of soil or 
water) might be collected to measure contamination in the environment at a specific location.  
 
Sample size  
The number of units chosen from a population or an environment.  
 
SIR 
The ratio of the observed number of cancer diagnoses in an area to the expected number of 
diagnoses multiplied by 100.  
 
Solvent  
A liquid capable of dissolving or dispersing another substance (for example, acetone or mineral 
spirits).  
 
Source of contamination  
The place where a hazardous substance comes from, such as a landfill, waste pond, incinerator, 
storage tank, or drum. A source of contamination is the first part of an exposure pathway.  
 
Special populations  
People who might be more sensitive or susceptible to exposure to hazardous substances because 
of factors such as age, occupation, sex, or behaviors (for example, cigarette smoking). Children, 
pregnant women, and older people are often considered special populations.  
 
Stability 
Stability in the context of an SIR refers to how the SIR changes when there are small increases or 
decreases in the observed or expected number of cases.  Two SIRs may have the same size but 
not the same stability.  For example, an SIR of 150 may represent 6 observed diagnoses and 4 
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expected diagnoses, or 600 observed diagnoses and 400 expected diagnoses.  (The SIR is the 
ratio of the number of observed diagnoses to the number of expected diagnoses multiplied by 
100.  For example, six divided by 4 equals 1.5 as does 600 divided by 400; 1.5 multiplied by 100 
equals 150.)  Both SIRs represent a 50 percent excess of observed diagnoses.  However, in the 
first instance, one or two fewer diagnoses would change the SIR a great deal, whereas in the 
second instance, even if there were several fewer diagnoses, the SIR would only change 
minimally.  When the observed and expected numbers of diagnoses are relatively small, their 
ratio is easily affected by one or two diagnoses.  Conversely, when the observed and expected 
numbers of diagnoses are relatively large, the value of the SIR is stable. 
 
Stakeholder  
A person, group, or community who has an interest in activities at a hazardous waste site.  
 
Statistics  
A branch of mathematics that deals with collecting, reviewing, summarizing, and interpreting 
data or information. Statistics are used to determine whether differences between study groups 
are meaningful.  
 
Substance  
A chemical.  
 
Substance-specific applied research  
A program of research designed to fill important data needs for specific hazardous substances 
identified in ATSDR's toxicological profiles. Filling these data needs would allow more accurate 
assessment of human risks from specific substances contaminating the environment. This 
research might include human studies or laboratory experiments to determine health effects 
resulting from exposure to a given hazardous substance.  
 
Superfund [see Comprehensive Environmental Response, Compensation, and Liability Act 
of 1980 (CERCLA) and Superfund Amendments and Reauthorization Act (SARA)  
 
Superfund Amendments and Reauthorization Act (SARA)  
In 1986, SARA amended the Comprehensive Environmental Response, Compensation, and 
Liability Act of 1980 (CERCLA) and expanded the health-related responsibilities of ATSDR. 
CERCLA and SARA direct ATSDR to look into the health effects from substance exposures at 
hazardous waste sites and to perform activities including health education, health studies, 
surveillance, health consultations, and toxicological profiles.  
 
Surface water  
Water on the surface of the earth, such as in lakes, rivers, streams, ponds, and springs [compare 
with groundwater].  
 
Surveillance [see public health surveillance]  
 
Survey  
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A systematic collection of information or data. A survey can be conducted to collect information 
from a group of people or from the environment. Surveys of a group of people can be conducted 
by telephone, by mail, or in person. Some surveys are done by interviewing a group of people 
[see prevalence survey].  
 
Synergistic effect  
A biologic response to multiple substances where one substance worsens the effect of another 
substance. The combined effect of the substances acting together is greater than the sum of the 
effects of the substances acting by themselves [see additive effect and antagonistic effect].  
 
Teratogen  
A substance that causes defects in development between conception and birth. A teratogen is a 
substance that causes a structural or functional birth defect.  
 
Toxic agent  
Chemical or physical (for example, radiation, heat, cold, microwaves) agents that, under certain 
circumstances of exposure, can cause harmful effects to living organisms.  
 
Toxicological profile  
An ATSDR document that examines, summarizes, and interprets information about a hazardous 
substance to determine harmful levels of exposure and associated health effects. A toxicological 
profile also identifies significant gaps in knowledge on the substance and describes areas where 
further research is needed.  
 
Toxicology  
The study of the harmful effects of substances on humans or animals.  
 
Tumor  
An abnormal mass of tissue that results from excessive cell division that is uncontrolled and 
progressive. Tumors perform no useful body function. Tumors can be either benign (not cancer) 
or malignant (cancer).  
 
Uncertainty factor  
Mathematical adjustments for reasons of safety when knowledge is incomplete. For example, 
factors used in the calculation of doses that are not harmful (adverse) to people. These factors are 
applied to the lowest-observed-adverse-effect-level (LOAEL) or the no-observed-adverse-effect-
level (NOAEL) to derive a minimal risk level (MRL). Uncertainty factors are used to account for 
variations in people's sensitivity, for differences between animals and humans, and for 
differences between a LOAEL and a NOAEL. Scientists use uncertainty factors when they have 
some, but not all, the information from animal or human studies to decide whether an exposure 
will cause harm to people [also sometimes called a safety factor].  
 
Urgent public health hazard  
A category used in ATSDR's public health assessments for sites where short-term exposures 
(less than 1 year) to hazardous substances or conditions could result in harmful health effects that 
require rapid intervention.  
 Appendix E, page 139 
 
Volatile organic compounds (VOCs)  
Organic compounds that evaporate readily into the air. VOCs include substances such as 
benzene, toluene, methylene chloride, and methyl chloroform.  
 
Other glossaries and dictionaries: 
Environmental Protection Agency (http://www.epa.gov/OCEPAterms/) 
 
National Center for Environmental Health (CDC) 
(http://www.cdc.gov/nceh/dls/report/glossary.htm) 
 
National Library of Medicine (NIH) 
(http://www.nlm.nih.gov/medlineplus/mplusdictionary.html) 
 
 
